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1SYNOPSIS
The survival rate of children with solid tumours is increasing. As a consequence
the late effects of cancer therapy have become an important issue requiring further 
research. The oral health of an individual is central to their general health, level of 
nutrition and quality of life. This study therefore set out to investigate:
 Whether or not the effects of cancer therapy resulted in a reduced level of oral 
health during and after treatment.  
 The need for dental input in comparison with the general population. 
 If patients had knowledge of the effects of cancer therapy on the oral cavity.
 If the oral health care needs of patients differed according to tumour type and 
treatment regime undertaken. 
The study group consisted of 120 patients aged 0-17 years, attending the solid 
tumour follow up clinic at Birmingham Children’s Hospital from July 2006-February 
2007. The complete study group was investigated and analysed, with stratification
according to tumour diagnostic group and medical treatment regime. The results 
were compared with national data from the 2003 office of national statistics Child 
Dental Health Survey.
The study had two main parts. Part A included a dental examination, and part 
B included a questionnaire completed by the parent/guardian. Demographic 
information was collected about each subject, cancer diagnosis, date of diagnosis, 
type of cancer therapy and time since completion of therapy.  Part A recorded the 
current oral health of each subject.  Caries prevalence, enamel opacities and 
gingivitis were recorded.  Part B utilised a questionnaire to assess the reported 
experience of the family regarding oral health care prior to, during and after cancer 
therapy. The parents/guardians perceived level of oral health input from the dental 
services and level of knowledge about the effects of cancer therapy on the oral cavity 
were also investigated. 
The results of this study demonstrated that the neuroblastoma diagnostic 
group and the high dose chemotherapy with stem cell rescue (HDCSCR) therapy 
group had greater oral health needs compared to the remaining study group and 
2general population. The level of decay in the primary dentition was increased in the 
neuroblastoma and HDCSCR groups. Microdont teeth were found in children who 
had received chemotherapy under the age of 3.5 years. There was a statistically 
significant relationship between the age at receipt of chemotherapy and the presence 
of microdont teeth. Thirty seven percent of the study group reported problems 
involving the oral cavity during cancer therapy with 40% demonstrating limited 
knowledge of potential future oral health complications.
This study concludes that oral health input is important for all patients suffering 
from a solid tumour. The possible adverse sequelae on the oral cavity are significant 
and arise both during and after cancer therapy. Children receiving chemotherapy 
under the age of 3.5 years should be warned of the possibility of microdontia in the 
permanent dentition. Extra attention should be directed towards those with a 
neuroblastoma or who are receiving HDCSCR. Clinical protocols and care pathways 
should be created for the oral health care of those patients suffering from a solid 
tumour. Specific and separate care pathways for neuroblastoma patients and those 
patients receiving HDCSCR should also be considered.
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1.0  INTRODUCTION, RELEVANT CURRENT LITERATURE,
HYPOTHESES, AIMS AND OBJECTIVES.
1.1 INTRODUCTION.
Childhood cancer is fortunately rare with the UK incidence rates being in the range of 
110-150 per million children per year. One in 500 children will be affected during the 
first 15 years of life (Stiller et al., 2004).  There has been a large reduction in mortality 
due to early diagnosis and improved treatment regimes. By the year 2000, 1 in 900 
adults aged 16-34 were survivors of childhood cancer (Stevens et al., 1998).
Estimates from the Childhood Cancer Research Group, University of Oxford suggest 
there are now over 10,000 known adult survivors of childhood cancer in the UK 
(Stevens et al., 1998).
In 2005 The National Institute for Health and Clinical Excellence published a 
document; Guidance on Cancer Services Improving outcomes in children and young 
people with Cancer (NICE, 2005a). This evidence based document acknowledged 
that cancer treatment can result in acute oral problems such as mucositis and other 
viral, bacterial and fungal oral infections. Later in life, previous cancer treatment can 
cause structural anomalies of the developing dentition. The document identified that 
oncology patients often have inadequate dental input during their illness and are later 
often lost to dental follow up (NICE, 2005a). It proposed that:
 Special provision for urgent dental treatment should be available before any 
chemotherapy is commenced.
 Information on the effects of cancer therapy should be given to all cancer 
patients and their families.
 A named professional should be identified to co-ordinate oral health care 
throughout cancer therapy.
 During the transition to adult services and there should be clear protocols and 
referral routes for oral care (NICE, 2005a).
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Further publications from The United Kingdom Children’s Cancer Study Group 
(UKCCSG) and the Paediatric Oncology Nurses Forum (PONF) in February 2006 
included evidence based guidelines about mouth care for children and young people 
with cancer (UKCCSG and PONF, 2006). These guidelines include suggestions
regarding oral health care at diagnosis of cancer, during therapy and after acute 
cancer treatment has finished. In particular advice is given on prevention and 
treatment of oral mucositis, oral candidosis, xerostomia and herpes simplex virus 
infections. These have been based on available current evidence (UKCCSG and 
PONF, 2006).
14
LITERATURE REVIEW.
1.2  CHILDHOOD CANCER AND CURRENT GUIDELINES.
Children’s cancers can be placed into three groups. These are leukaemias, central 
nervous system tumours and the so called ‘solid tumours’. The present study focused
on the solid tumour group which in this investigation also included children with 
Hodgkin’s lymphoma and non-Hodgkin’s lymphomas. This group was studied 
specifically as there is limited research in the literature to date with most of the 
research being focused on the leukaemias. Tumours are named according to their
constituent cells. They include sarcomas (cancers arising from connective or 
supporting tissues such as muscle or bone), embryonal tumours (malignant 
counterparts of cells usually expressed during normal fetal development),
carcinomas (malignant tumours originating from epithelial and glandular cells), and 
lymphomas (cancers of organs which produce and store cells of the lymphoid system 
for example lymph nodes), (NCI, 2005). In general, one third (32%) of childhood 
cancers will be leukaemia’s, 10% lymphomas, 24% brain and spinal tumours and 
15% embryonal tumours (such as: neuroblastoma, retinoblastoma, Wilm’s tumour 
and hepatoblastoma). The remaining 19% comprise other types of cancer (Stiller et 
al., 2004).
Survival rates following treatment are increasing and, therefore, the late effects of 
childhood cancer are becoming increasingly important. Childhood cancer and its 
treatment can have a significant effect upon the physical, social and emotional well 
being of the child and thus their quality of life. Late effects include: endocrine damage 
resulting in growth disorders; pubertal failure or precocious puberty; inadequate bone 
mineralization; and discreet hormone deficiencies requiring replacement (Stevens et 
al., 1998, NICE, 2005a).
The oral health and therefore healthcare of these individuals has a significant impact 
upon their quality of life during their cancer therapy. If acute dental problems do arise 
they are difficult to manage. Many such problems are preventable if children are seen 
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by the dental team before commencing cancer therapy. Clarkson and Eden 
investigated the dental health of children with cancer. In a study of 60 children, 4-6 
months post diagnosis, 21 required urgent dental treatment. In their conclusion the 
authors highlighted the need to improve the integration of dental services into the 
medical care pathways (Clarkson and Eden, 1998). Evidence regarding the effects of 
cancer therapy from the literature is weak and varied. Many studies demonstrate that
patients who have received chemotherapy have disturbances in their dentitions
(Duggal, 2003, Marec-Berard et al., 2005, Purdell-Lewis et al., 1988, Minicucci et al., 
2003, Holtta et al., 2002, Nasman et al., 1997). Other studies have revealed the only 
significant effects to be small areas of enamel hypoplasia or opacities (Alpaslan et 
al., 1999, Nunn et al., 1991). There are a limited number of studies investigating the 
different solid tumour groups of patients, with much of the literature being based 
around patients with leukaemia.
In 2005 the National Institute for Health and Clinical Excellence (NICE) published 
Guidance on Cancer Services “Improving outcomes in children and young people 
with Cancer” (NICE, 2005a). This evidence based document acknowledged that
cancer treatment can also result in acute oral problems such as mucositis and other 
viral, bacterial and fungal infections. Later in life historical cancer treatment can be 
associated with structural anomalies of the developing dentition. The document 
identified that oncology patients often have inadequate dental input during their 
illness and are later often lost to dental follow up despite the seriousness of their 
condition. The recommendations made by NICE (NICE, 2005a) were:
 to ensure special provision for emergency dental treatment is available prior to 
the commencement of chemotherapy,
 that information on the effects of cancer therapy should be given to all cancer 
patients and their families,
 that a named professional should be identified to co-ordinate care throughout 
cancer therapy and during the transition to adult services,
 to have clear protocols and referral routes for dental care.
The document also states there is very little good quality evidence on the 
effectiveness of treatments for oral infections and oral mucositis.
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In February 2006 The United Kingdom Children’s Cancer Study Group (UKCCSG) 
and the Paediatric Oncology Nurses Forum (PONF) produced evidence based 
guidelines about mouth care for children and young people with cancer (UKCCSG 
and PONF, 2006). This guideline covers oral care at the time of cancer diagnosis,
oral hygiene at diagnosis and during cancer treatment, dental/oral care during and 
after cancer treatment, plus advice on the prevention and treatment of oral mucositis, 
oral candidosis, xerostomia and infections with the herpes simplex virus (UKCCSG 
and PONF, 2006). This advice was based on the current available evidence. The 
mucositis recommendations for treatment are, at best, based on evidence level B 
and include best practice (clinical expertise of the guideline group). The candidosis 
and xerostomia recommendations are based on evidence level D (case series and 
cross sectional studies) and herpes simplex advice is based on evidence levels 
ranging from A to D (UKCCSG and PONF, 2006).
Maintaining a good standard of oral health is important for all children. The UK Child 
Dental Health Survey 2003 (CDHS) found 43% of 5-year-olds and 57% of 8-year-
olds had experienced obvious caries in primary teeth (Lader et al., 2005). In the 
permanent dentition 14% of 8-year-olds, 34% of 12-year-olds and 49% of 15-year-
olds had experienced obvious caries (Pitts and Harker, 2005). With this knowledge 
on the state of children’s general dental health, it highlights the importance of dental 
input before, during and after cancer therapy. The effects of cancer treatment are 
well known to be associated with oral complications (Cheng et al., 2002) and cause 
other generalised medical complications such as neutropenia and thrombocytopenia
(Maguire and Welbury, 1996). Therefore, the management of any oral problem 
becomes more challenging in the presence of these additional risk factors.
The literature covering the effects of cancer therapy on the oral cavity is limited. 
Studies employ small sample sizes due to the nature of the disease and large 
numbers of confounding factors within the groups makes comparison between 
studies difficult. The majority of the literature is based on patients who have been 
treated for leukaemia with fewer studies on solid tumour patients.
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1.3 STAGES OF DENTAL DEVELOPMENT.
The stage of dental development at the time of cancer diagnosis and subsequent 
surgery and chemotherapy is an important consideration. Cancer therapy is more 
likely to have a permanent effect during the early stages of tooth development. This 
section will therefore briefly explore the stages and timings of tooth development 
before exploring the available literature.
1.3.1 Dental development.
Dental development in humans begins in utero at 5-6 weeks and continues until the 
roots of the wisdom teeth are fully formed 20-25 years later. It is a prolonged process 
and can be affected by both external (trauma, radiation) and internal factors
(chemotherapy, antibiotics, fever, metabolic disturbances, and genetic disturbances).
The impact of cancer therapy upon dental development is likely to depend on the 
timing, severity and duration of the causative factor (Maguire and Welbury, 1996).
The first sign of tooth development is an epithelial thickening of the mandible and 
maxilla. The initiation of deciduous teeth begins during the second and third month in 
utero (RCSEng, 1998). Tooth development then occurs in 3 main stages. First 
“initiation” begins and tooth germs appear along an invagination of oral epithelium 
called the dental lamina. This is followed by “morphogenesis” where the shape of the 
tooth is determined. Finally, “histogenesis” begins, which is the process of 
differentiation of cells and the final dental tissues are formed (Berkovitz et al., 1992).
The tooth germ consists of the enamel organ which gives rise to the stellate 
reticulum, intermediate reticulum, inner enamel epithelium and outer enamel 
epithelium. The inner enamel epithelium then forms ameloblasts and enamel. The 
dental papillae subsequently create the odontoblasts and dentine and the dental 
follicle produces the periodontal ligament fibroblasts, cementoblasts and cementum, 
and the osteoblasts and alveolar bone.  The development of a tooth germ into a fully 
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formed tooth involves complex interactions between the epithelium of the enamel 
organ and the mesenchyme of the dental papillae (Berkovitz et al., 1992).
Production of the mineralised tissues involves initial secretion of an organic matrix 
and then deposition of mineral within the matrix. The dentine matrix develops before 
the enamel matrix.  In dentine, odontoblasts form a collagen matrix which is then 
mineralised.  Enamel is formed by ameloblasts in a similar fashion to dentine. The 
organic material comprises a protein called ameolgenin which is gradually removed 
as the mineral ions are added.
Root development starts when crown formation is complete and occurs by an apical 
growth of the root sheath of Hertwig. Root growth is usually two thirds complete on 
tooth eruption and continues after eruption of the tooth for up to 3 years (Berkovitz et 
al., 1992). During this time the supporting structures of the tooth also form. These 
consist of root cementum, alveolar bone, periodontal ligament and gingivae
(RCSEng, 1998). The overall process from initiation to complete permanent tooth 
development takes at least 10 years (Beek, 1983).
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1.3.2 Disorders of development.
Disorders in dental development can be due to abnormalities in the differentiation of 
the dental lamina and tooth germs resulting in differences in the number, size and 
form of teeth, or problems in the process of tooth development which results in 
structural deformities of a particular tooth depending on the time of the insult
(RCSEng, 1998).
Individual tooth development is an extremely sensitive process and when disturbed 
can profoundly affect the individual developing tooth. Defects are described as 
“hypoplastic” or “hypocalcified”. A hypoplastic tooth means there is a disturbance in 
the normal prism patterns. A hypocalcified tooth is where the enamel is of normal 
thickness but is extremely soft and soon lost due to the forces of abrasion and 
erosion (RCSEng, 1998).
Throughout the whole tooth development process, disturbances can occur resulting 
in missing teeth, dental anomalies and poor root formation. These can arise due to 
both systemic or local insults. The literature to date is varied with regards to the 
effects of cancer therapy on the developing dentition. Effects thought to be attributed 
to chemotherapy include: arrested root development, enamel defects, discolorations, 
microdontia and agenesis (Oguz et al., 2004). The extent of disturbance is likely to 
depend on the stage of development of the teeth at the time of insult. Table 1.1 
illustrates the timings of crown and root development for children’s teeth.
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Table 1.1 Timing of tooth development in both deciduous and permanent teeth
(Beek, 1983). All ages post full term delivery unless otherwise specified.
Tooth Initial 
Calcification
Completion of 
crown
Eruption Completion of 
root
Deciduous 
maxillary first 
molar
5 months in 
utero
6 months 12-16 months 2-2.5 years
Deciduous 
mandibular 
first molar
5 months in 
utero
6 months 12-16 months 2-2.5 years
Deciduous 
maxillary
second molar
6 months in 
utero
10-12 months 1.75-2.5 years 3 years
Deciduous 
mandibular 
second molar
6 months in 
utero
10-12 months 1.75-2.5 years 3 years
Maxillary 
central incisor
3-4 months 4-5 years 7-8 years 10 years
Mandibular 
central incisor
3-4 months 4-5 years 6-7 years 9 years
Maxillary 
lateral incisor
10-12 months 4-5 years 8-9 years 11 years
Mandibular 
lateral incisor
3-4 months 4-5 years 7-8 years 10 years
Maxillary 
canine
4-5 months 6-7 years 11-12 years 13-15 years
Mandibular 
canine
4-5 months 6-7 years 9-10 years 12-14 years
Maxillary first 
premolar
1.5-1.8 years 5-6 years 10-11 years 12-13 years
Mandibular 
first premolar
1.75-2 years 5-6 years 10-12 years 12-13 years
Maxillary 
second 
premolar
2-2.5 years 6-7 years 10-12 years 12-14 years
Mandibular 
second 
premolar
2.25-2.5 years 6-7 years 11-12 years 13-14 years
Maxillary first 
molar
Birth or slightly 
before
2.5-3 years 6-7 years 9-10 years
Mandibular 
first molar
Birth or slightly 
before
2.5-3 years 6-7 years 9-10 years
Maxillary 
second molar
2.5-3 years 7-8 years 12-13 years 14-16 years
Mandibular 
second molar
2.5-3 years 7-8 years 12-13 years 14-16 years
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1.4 CLASSIFICATION OF SOLID TUMOURS.
The National Cancer Intelligence Centre at the Office for National Statistics (NCIC-
ONS) collates cancer registration data for Great Britain. All new cases of cancer each 
year are registered. The data is coded using the International Classification of 
Diseases system (ICD) version 10. This system uses a topographical description of 
the tumour site and allows detailed coding of adult tumours.
As childhood cancers are different to those in adult life they are classified by an 
alternative system. This classification system is called the International Classification 
of Childhood Cancer (ICCC) and is based on the histological characteristics of the 
tumour (Kramarova et al., 1996). The ICCC is illustrated in table 1.2.
Table 1.2 International Classification of Childhood Cancer (ICCC) (Kramarova et al., 
1996).
I Leukemia (a) Lymphoid Leukemia  Excluding Acute Lymphoblastic 
Leukaemia (ALL)
(b) Acute Leukemia  Excluding Acute Myeloid 
Leukaemia (AML)
(c) Chronic Myeloid Leukemia
(d) Other Specified Leukemia’s
(e) Unspecified Leukemia’s
II Lymphomas and (a) Hodgkin’s disease
Reticuloendothelial (b) Non-Hodgkin’s lymphomas
Neoplasms. (c) Burkitt’s lymphoma
(d) Miscellaneous lymphoreticular neoplasms
(e) Unspecified lymphomas
III Central Nervous (a) Ependymoma
System (CNS) and (b) Astrocytoma
Miscellaneous (c) Primitive neuroectodermal tumours
Intracranial and (d) Other gliomas
Intraspinal Neoplasms (e) Miscellaneous intracranial and intraspinal neoplasms
(f) Unspecified intracranial and intraspinal neoplasms
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IV Sympathetic Nervous (a) Neuroblastoma and ganglioneuroblastoma
System Tumours (b) Other sympathetic nervous system tumours
V Retinoblastoma
VI Renal Tumours (a) Wilm’s’ tumour, rhabdoid and clear cell sarcoma
(b) Renal carcinoma
(c) Unspecified malignant renal tumours
VII Hepatic Tumours (a) Hepatoblastoma
(b) Hepatic carcinoma
(c) Unspecified malignant hepatic tumours
VIII Malignant Bone (a) Osteosarcoma
Tumours (b) Chrondosarcoma
(c) Ewing’s sarcoma
(d) Other specified malignant bone tumours
(e) Unspecified malignant bone tumours
IX Soft-Tissue Sarcomas (a) Rhabdomyosarcoma and embryonal sarcoma
(b) Fibrosarcoma, neurofibrosarcoma and other 
fibromatous neoplasms
(c) Kaposi’s sarcoma
(d) Other specified soft-tissue sarcomas
(e) Unspecified soft-tissue sarcomas
X Germ-Cell, (a) Intracranial and intraspinal germ-cell tumours
Trophoblastic and other 
Gonadal Neoplasms
(b) Other and unspecified non-gonadal germ-cell
      tumours
(c) Gonadal germ-cell tumours
(d) Gonadal carcinomas
(e) Other and unspecified malignant gonadal tumours
XI Carcinomas and other (a) Adrenocortical carcinoma
Malignant Epithelial (b) Thyroid carcinoma
Neoplasms (c) Nasopharyngeal carcinoma
(d) Malignant melanoma
(e) Skin carcinoma
(f) Other and unspecified carcinomas
XII Other and
Unspecified Malignant
(a) Other specified malignant tumours
Neoplasms (b) Other unspecified malignant tumours
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1.4.1   Common solid tumour categories.
 Brain and spinal tumours.
 Neuroblastomas.
 Retinoblastomas.
 Wilm’s tumour.
 Hepatoblastoma.
 Lymphomas (Hodgkin’s and non-Hodgkin’s).
 Osteosarcoma.
 Ewing’s Sarcoma.
 Rhabdomyosarcoma.
 Germ cell tumours.
1.5 EPIDEMIOLOGY OF SOLID TUMOURS.
Epidemiology literally means ‘studies upon people’. It is a science concerned with the 
study of factors causing and influencing disease within a population (Farmer et al., 
1996).  Since 1962 children diagnosed with cancer in Great Britain should have been 
registered in a national data base. It should be noted however that at present 
registration of cancer cases is voluntary.  The National Cancer Intelligence Centre at 
the Office for National Statistics (NCIC-ONS) collate cancer registration data for 
England, Scotland and Wales. The National Registry of Childhood Tumours (NRCT) 
in Oxford registers those cases in children under 15 years of age in the UK.  The 
United Kingdom Children’s Cancer Study Group (UK-CCSG) now renamed The 
Children’s Cancer and Leukaemia group (CCLG) have also collected data of all 
registrations of childhood cancer for children under 15 years of age from 1977-2005.
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1.5.1 Prevalence.
The prevalence of a disease is the number of existing cases of a particular disease in 
a given population at a given time or during a specified period (Farmer et al., 1996). 
Therefore the prevalence of specific childhood cancers is dependant upon both the 
incidence of the cancer and the rates of survival.  
Cancers in children account for less than 1% of all cancers in industrialised countries
(Stiller and Draper, 1998). The NRCT states between 1988-1997 the incidence of a 
childhood cancer was 133.7 per million (includes a small number of non-malignant 
diagnoses) (NICE, 2005a). The chance therefore of a child being diagnosed with 
cancer before the age of 15 is 1 in 500. This figure is derived from risks of about 1 in 
1600 for leukaemia, 1 in 2200 for a brain or spinal tumour and 1 in 1100 for all other 
cancers combined (CCRG., 2004).  Table 1.3 shows recent data from CCLG to show 
the number of cases of childhood cancer to be registered in the UK 2000-2005 (a six 
year period).
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Table 1.3  Total number of childhood cancer cases for children under 15, registered 
in the UK 2000-2005 (CCLG, 2007c).
Cancer type ICCC code Number
Leukaemia I 3002
Lymphomas II 966
CNS III 2131
SNS IV 593
Retinoblastoma V 240
Renal VI 569
Hepatic VII 116
Bone VIII 388
Soft tissue sarcoma IX 595
Germ-cell X 273
Epithelial XI 135
Other malignant XII 17
Other non-malignant LCH;FIB 810
Total 9835
CNS- central nervous system.
FIB- fibromatosis.
LCH- langerhans cell histiocytosis.
SNS- sympathetic nervous system.
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Figure 1.1 Prevalence of childhood cancer in children under 15 registered in the UK 
2000-2005 by tumour type (CCLG, 2007c).
The prevalence of childhood cancer in children under 15 in the UK 
2000-2005 by tumour type.
Leukaemia
Lymphomas
CNS
SNS
Retinoblastoma
Renal
Hepatic
Bone
Soft tissue 
sarcoma
Germ-cellEpithelial
Other malignant
LCH/FIB
Leukaemia Lymphomas CNS SNS
Retinoblastoma Renal Hepatic Bone
Soft tissue sarcoma Germ-cell Epithelial Other malignant
LCH/FIB
Solid tumours in the UK therefore accounted for 6833 out of 9853 (69%) cases of 
cancer in children under 15 years old from 2000-2005 (CCLG, 2007c). 
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1.5.2 Age variance at diagnosis.
Childhood cancer has a peak incidence at around 5 years of age (Stiller and Draper, 
1998). The lowest incidence was in the 8-10 year old group (Stiller, 2002). Cancer is 
more common in adolescents (aged 15-19 years) than in children aged 8-10 years. It 
is more common again in young adults (20-24 years) with an incidence here of 226 
per million compared to 150-200 per million in the 15-19 age group (Stiller, 2002, 
Birch et al., 2002). The peak incidence of neuroblastoma, retinoblastoma and 
hepatoblastoma is under the age of 1 year. Wilm’s tumour is most prevalent at 3 
years of age.   Osteosarcomas and Hodgkin’s disease are uncommon under the age 
of 2 years but do increase in incidence beyond this age (NICE, 2005b).
1.5.3 Trends.
An increased incidence of childhood cancer has been reported in males (Cotterill et 
al., 2000, Birch et al., 2002).  UK studies report a 1.2:1 M:F ratio in children aged 0-
14 years (Parkin et al., 1998). As a whole, there has been a general increase in the 
incidence of childhood and adolescent cancer. This is especially significant for the 
15-24 year old group (Birch et al., 2002). In the North West of England a linear 
increase in incidence of acute lymphoblastic leukaemia and Hodgkin’s disease had 
been identified (Blair and Birch, 1994a). A similar study also in the north West of 
England showed an increased incidence of astrocytoma, medulloblastoma, 
neuroblastoma and non-skin epithelial tumours (Blair and Birch, 1994b).
1.5.4 Mortality.
Children aged 0-14 years with leukaemia are the group with the highest reported 
mortality rate because they are the group with the highest incidence of cancer.  
Figures obviously vary between groups depending on the nature of the tumour. For 
example, tumours of the sympathetic nervous system account for 12.3% of deaths 
but only contribute to 6.7% of new childhood cancer cases each year, whereas 
retinoblastoma accounts for 3.2% of new cases but only 0.8% of deaths 
demonstrating a more favourable survival rate (NICE, 2005a).
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1.5.5 Survival.
Generally, survival rates from childhood cancer have increased over the past 30 
years due to improved treatment regimes and are now as high as 70-75% (Gatta et 
al., 2002). Again the survival rate will vary according to the diagnosis. 100% survival 
rate is reported in thyroid carcinomas whereas neuroblastomas are reported at 55% 
and brain and spinal tumours at 43% (NICE, 2005a).
1.5.6 West Midlands data.
There are 5 specialist paediatric regional registries in England. These cover the 
North-Western, Northern, Yorkshire, West Midlands and South West regions. In 1984 
a West Midlands Regional Children’s Tumour Registry (WMRCTR) was established 
at Birmingham Children’s Hospital (Muir et al., 1992).
In the West Midlands the distribution of childhood cancer is similar to the pattern in 
other developed countries. The most recent literature specific to the West Midlands 
states of the 1310 cases diagnosed between 1994-2003, 32% were leukaemias, 25% 
brain/CNS tumours, 10% lymphomas and 33% other solid tumours (Powell et al., 
2004). The West Midlands group also showed a similar incidence between males 
and females and the age at diagnosis matched the national statistics (Powell et al., 
2004).
1.6 AETIOLOGY OF SOLID TUMOURS.
The aetiology of childhood cancers remains largely unknown. It has been suggested 
by some authors that the aetiology and factors influencing disease progression in 
childhood cancers is different to those occurring in adults. For example tobacco and 
alcohol are known risk factors for oral squamous carcinoma in adults however this is 
also a disease that has increased in incidence among children worldwide in the last 
few decades. It is unknown why children, despite such a limited time of exposure to 
known carcinogenic risk factors experience similar cancerous lesions therefore 
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suggesting possible different disease processes (Llewellyn et al., 2001). For cancer 
to develop, tumour initiation and tumour progression must occur. The rate at which 
this occurs depends on changes in the cell and changes in the host. (Franks and 
Teich, 1997). The putative risk factors include genetics,  infections, hormones and 
radiation  (NICE, 2005a).
1.6.1 Genetics.
Around 5% of childhood malignancies are related to an inherited genetic tendency
(NICE, 2005b). For example a somatic mutation in the retinoblastoma gene can 
cause an autosomal dominant inheritance of retinoblastoma  with an 100% increase 
in the risk of osteosarcoma (Draper et al., 1992) and a somatic defect in the P53 
tumour suppressor gene results in an increased risk of a number of sarcomas and 
carcinomas resulting in the Li-Fraumeni family cancer syndrome (Birch, 1994). 
Fanconi’s anaemia (FA) is a rare autosomal recessively inherited condition involving 
defects in DNA repair. Subsequently patients suffer from congenital abnormalities 
and developmental abnormalities, progressive bone marrow failure and have a 
predisposition to cancer particularly acute myeloid leukaemia and solid tumours. 
(Franks and Teich, 1997, Rosenberg et al., 2003, Salum et al., 2006). There is a high 
incidence of oral squamous cell carcinoma in FA patients (Oksuzoglu and Yalcin, 
2002, Lustig et al., 1995).
1.6.2 Infections.
Infections particularly by viruses are thought to play a role in the development of 
certain types of cancer. Associated with Epstein virus are Burkitt's lymphoma, 
Hodgkin's disease and nasopharyngeal carcinoma. Associated with human 
immunodeficiency virus and human herpes virus 8 is Kaposi’s sarcoma. Hepatitis B 
virus is associated with liver carcinoma (CCRG, 2005).
The causes of childhood cancer are complex and probably multifactorial. Within the 
literature there are very few conclusive studies and it has been identified in many 
papers as an area which requires further investigation (Anderson, 2006).
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1.7 SIDE EFFECTS OF TREATMENT WITH SPECIFIC REFERENCE TO THE 
ORAL SIDE EFFECTS.
The treatment of solid tumours usually involves surgery and chemotherapy and/or 
radiotherapy to the area affected.  The aim of cancer therapy is obviously to destroy
live but abnormal cells. Blood borne therapy will therefore, have an effect on all other 
living tissues and in particular rapidly dividing cells of the oral cavity.
Radiotherapy is used to destroy tumour cells that are reproducing at a rate higher 
than normal cells. Cell sensitivity to radiation depends on which part of the cell cycle 
they are at. The most susceptible cells are those in a state of increased mitotic 
activity in the cell cycle. The higher the dose of radiation the more cells are affected. 
The effects are cumulative and dependent on the dose. If the dose is high enough, 
the ameloblasts and odontoblasts will die regardless of the position of the cell cycle. 
This is the cause of tooth agenesis and arrested tooth development (Zarina and Nik-
Hussein, 2005). Radiotherapy is targeted at a specific area of the body during cancer 
therapy. Away from the oral cavity, radiotherapy treatment does not cause effects 
within the oral cavity.
Chemotherapy also attempts to destroy tumour cells. It is toxic to actively proliferating 
cells by interfering with DNA synthesis and replication, RNA transcription and 
cytoplasmic transport mechanisms. Chemotherapeutic agents cause damage 
according to their dose and repetition of the agent. Odontoblasts and ameloblasts in 
susceptible phases of the cell cycle can be damaged easily. Cells in the non-
proliferative stage should remain unaffected and continue to develop normally. This 
is different to radiotherapy where all cells in the path of the beam are destroyed. 
Chemotherapy is a systemic treatment and therefore the oral tissues are necessarily
involved (Nasman et al., 1997, Zarina and Nik-Hussein, 2005).
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Children are also often treated with adjunctive steroids. In the short term this can 
increase appetite, and therefore can cause more frequent acid attacks on the teeth.
Long term steroids can reduce bone mineralization and may affect growth (Lai et al., 
2000, Hoorweg-Nijman et al., 1999).
Oral side effects arise due to a direct effect of the chemotherapy drug on the oral 
mucosa and an indirect effect due to myelosuppression. Direct effects usually occur 
7-14 days following therapy and indirect effects 12-14 days later and will commonly 
result in infection and haemorrhage (Chen et al., 2004). The oral mucosa is 
particularly susceptible due to the high cell turnover rate. Oral complications 
significantly affect the child’s quality of life and when severe can interfere with 
treatment regimes or cause further complications such as septicaemia (Cheng et al., 
2002).
Acute effects of chemotherapy include:
 Nausea.
 Vomiting.
 Malabsorption.
 Mucositis.
 Myelosuppression- thrombocytopenia, neutropenia, anaemia.
 Periodontal and soft tissue infections.
 Cytotoxic effects e.g. mucositis and reduced salivary gland function.
 Alopecia.
 Nutritional deficiencies.
 Neurological- trismus and jaw pain, weakness of the facial muscles. (Maguire 
and Welbury, 1996).
During cancer therapy children are often significantly unwell. A high calorie diet is 
usually required to maintain sufficient energy levels and to prevent significant weight 
loss (Doyle et al., 2006). These children are likely to receive a highly cariogenic diet 
during the time they are unwell. Frequent intakes of high calorie and sugary foods will 
be advocated increasing the number of daily acid attacks to the teeth, thus increasing 
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the caries risk (Cancer Research, 2007). Throughout this time the child will also be 
subject to many different medical investigations some of which are unpleasant. In the 
Birmingham Children’s Hospital (BCH) unit children are given sweets and chocolates 
as a reward for cooperating with medical interventions thus increasing the caries risk 
further.  A painful oral cavity may compromise the ability to provide adequate oral 
debridement. If plaque and debris are not removed there is increased risk of further 
ulceration, infection and dental caries (Kennedy and Diamond, 1997).
1.7.1 Xerostomia.
Chemotherapeutic drugs can alter the flow and composition of saliva.  This is usually 
evident 7-10 days after chemotherapy (Chen et al., 2004). The effects result in taste 
disturbances, difficulty in chewing and swallowing, speech problems and oral 
discomfort, together with a significant effect on the patient’s quality of life (UKCCSG 
and PONF, 2006). Patients experiencing xerostomia will also be at greater risk of oral 
infections such as candidosis and dental caries (UKCCSG and PONF, 2006, Epstein 
and Chow, 1999).
1.7.2 Mucositis.
This is inflammation and ulceration of the mucous membranes, and has been shown 
to occur in 30-75% of patients undergoing chemotherapy (Fulton et al., 2002, Dodd 
et al., 2000). Mucositis is known to be associated with a high morbidity and may 
often affect the patient’s tolerance of treatment and therefore compromise their 
overall medical therapy. It can frequently result in hospital admission for fluid 
replacement and pain control and is known to increase the risk of septicaemia to up 
to four times that of a patient not suffering from mucositis (Cheng et al., 2002).
Mucositis may also predispose the individual to other oral infections leading to 
systemic infections (UKCCSG and PONF, 2006, Dodd et al., 2000).
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1.7.3 Fungal infection.
Oral fungal infections are commonly caused by candida albicans. This is a 
commensal organism which can cause infections of the mouth particularly during 
periods of host immunosuppression. Mucositis, xerostomia and poor oral hygiene 
can all contribute to the patient’s risk of developing candidosis. The plaques present
commonly on the buccal mucosa, dorsal tongue and palate. They are creamy white 
patches which are easily wiped off leaving an erythematous, eroded or ulcerated 
surface. The plaques can increase in number and size and may lead to further 
systemic infection (UKCCSG and PONF, 2006, Alberth et al., 2006).
1.7.4 Herpes simplex virus.
During cancer therapy, especially when immunocompromised, children may be more 
susceptible to infection with human herpes simplex virus (Ramphal et al., 2007). This 
can range from a cold sore type lesion to primary herpetic gingivostomatitis. There is 
a risk it can spread and develop into a systemic infection or that the vesicles become 
secondarily infected with bacteria (UKCCSG and PONF, 2006).
1.7.5 Long term effects.
1.7.5.1 Dental caries.
Radiation to the jaws is known to produce xerostomia and therefore render the 
individual more prone to caries (Franzel et al., 2006). The effects of chemotherapy 
regarding dental caries are largely unknown. Teeth could be more prone to decay as 
sweets are often given as rewards and diet and nutrition is more varied during 
treatment. There are several reports in the literature comparing the level of dental
decay in patients who have received chemotherapy. Nunn et al (1991) looked at 52 
children in remission from cancer and their siblings and found no difference in the 
level of decay between those who had experienced chemotherapy and their siblings 
in primary and secondary dentitions (Nunn et al., 1991). Alpaslan et al (1999) studied 
the dental disturbances of 30 survivors of childhood lymphoma and compared them 
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to 20 controls and also found no significant difference between the control and study 
group (Alpaslan et al., 1999). Maguire et al (1987) investigated 52 children and their 
siblings and found no difference in the level of dental decay between the 2 groups
(Maguire et al., 1987). However a study concerning 52 children who had been 
treated for neuroblastoma found the primary dentition showed a greater caries rate 
than the national average but this was not the case for permanent teeth where caries 
prevalence was found to be the same as the general population. The patients with 
dental caries were found to have excessive carbohydrate intake and poor oral 
hygiene levels (Kaste et al., 1998). The largest amount of caries noted was in the 
Purdell-Lewis study (1988) where they found the study group had three times as 
many carious lesions as the control group (Purdell-Lewis et al., 1988). The studies 
described above utilising a control group used the same criteria for the examination 
of caries in the study group and control group allowing comparisons within the study 
(Maguire et al., 1987, Purdell-Lewis et al., 1988, Nunn et al., 1991, Alpaslan et al., 
1999). However Kaste et al (1998) though referencing the index for caries used does 
not mention if this is the same index as used in the epidemiological data she draws 
comparison with (Kaste et al., 1998).   Contrasts between studies are therefore 
difficult to draw as the same indices for caries diagnosis are not consistently used 
throughout the literature.
1.7.5.2 Gingival health.
In several studies no significant difference was found in the gingival health between 
the study group and the control groups (Alpaslan et al., 1999, Nunn et al., 1991, 
Maguire et al., 1987). Nunn et al (1991), Maguire et al (1987) and Alpaslan et al 
1999) all used the Löe gingival index in their assessments to assess the gingival 
condition. This index records qualitative changes in the gingival soft tissue only and 
does not consider any periodontal changes (Loe, 1967). Maguire et al (1987) found 
no significant difference between the control and study group for gingival health but 
did find in both groups there was a significant correlation of gingivitis with age. The 
lowest scores being in the younger ages of both groups (Maguire et al., 1987).
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1.7.5.3 Enamel hypoplasia and discolourations.
The prevalence of enamel hypoplasia and discolourations between control and study 
groups for those patients who had survived malignant disease was found to be 
increased in all studies but the significance of this varied. Alpaslan et al (1999) 
studied 30 children and found enamel hypoplasia’s in 64 teeth in 14 patients and 
discolorations in 147 teeth in 17 patients. In the control group of 20 healthy 
volunteers 5 teeth in 3 volunteers exhibited enamel hypoplasia’s and 4 teeth in 1 
volunteer exhibited discolouration. The prevalence of enamel hypoplasia’s and 
discolouration was significantly different between groups. In the report of the study it 
states the teeth were dried and enamel defects and discolourations were recorded. 
There is no indication of criteria used therefore making direct comparisons of this 
study with other studies unreliable (Alpaslan et al., 1999). Maguire et al (1987) and 
Nunn et al (1991) both used the Murray and Shaw method (Murray and Shaw, 1979)
making direct comparisions between studies possible. The index consists of scores 
1-7 and examines the occlusal, buccal and lingual surface of each tooth (Loe, 1967).  
Maguire et al (1987) found a higher prevalence of enamel opacities and hypoplasia in 
the study group but only in the maxillary teeth. The control group showed milder 
degrees of enamel opacities with the study group showing more horizontal lines and 
hypoplasia (Maguire et al., 1987). Nunn et al (1991) found more children in the study 
group had enamel opacities and hypoplasia but the overall difference between the 
study group and control (siblings) group was not significant. (Nunn et al., 1991).
1.7.5.4 Crown and root malformations.
Many studies have shown evidence of taurodontism, microdontia, thin roots and root 
constrictions (Nunn et al., 1991, Alpaslan et al., 1999, Maguire et al., 1987, Kaste et 
al., 1998). Maguire et al (1987) reported that in all cases where the radiographic 
findings showed failure of root development this could be attributed to a time when 
the child was receiving medical treatment for a malignancy. They found that 
treatment given during the first 3.5 years of life was most likely to affect the dental 
lamina and crown formation thus resulting in a small tooth (Maguire et al., 1987).
Nunn et al (1991) found 16% of their study population to have thin roots (Nunn et al., 
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1991). Alpaslan et al (1999) found there to have been root malformations on 23 teeth 
in 9 children out of a study group of 30 children, but found no microdontia or crown 
malformations. There was some evidence of premature apexification and therefore 
short roots, but this was not a significant difference (Alpaslan et al., 1999). Kaste et al 
(1998) found 71% of the study group of 52 patients had radiographic dental 
abnormalities, which included small roots, small teeth and hypoplasia (Kaste et al., 
1998).  A study looking at the effects of chemotherapy in Wilm's tumour patients also 
found 77% to have experienced dental anomalies comprising microdontia, excessive 
caries, root stunting, hypodontia and hypoplasia (Marec-Berard et al., 2005). Nasman 
et al (1997) found in their chemotherapy group there was a reduction in the mean 
root area of all teeth except the canines; the crown areas however did not seem to be 
affected (Nasman et al., 1997).  Purdell-Lewis et al (1988) commented that the 
findings of different surveys cannot be compared due to different criteria used in 
diagnosing anomalies radiographically and the different ages of patients (Purdell-
Lewis et al., 1988), a common problem seen throughout the available literature.
Despite this there is general agreement in the literature that chemotherapy can have 
an effect on the crown and root malformation of teeth.
1.7.5.5 Unerupted teeth.
Purdell–Lewis et al (1988) found in a study of 45 children who had received 
chemotherapy for malignancies, that the test patients had fewer erupted teeth than 
the control group. At aged 7 years they had an average of 4 fewer teeth and by age 
11 years they had 7 fewer teeth. The control in this paper was the national 
epidemiological studies of 2 towns in the Netherlands (n=300) using the same indices
(Purdell-Lewis et al., 1988). Alpaslan et al (1999) reported that differences between 
study and control groups for unerupted teeth were not statistically significant but they 
did not explain the criteria used to define an unerupted tooth. Because the age range 
was 4-15 years and in many patients one would expect a number of unerupted teeth 
to be present anyway (Alpaslan et al., 1999).  
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1.7.5.6 Hypodontia.
Alpaslan et al (1999) again showed evidence in their study group that more children 
had missing teeth when compared with the controls; 48 teeth were missing in 12 
children but, 38 of these were wisdom teeth and it was unclear in this study whether 
the younger children in whom one would not expect to see wisdom teeth were 
included or not (Alpaslan et al., 1999). Nunn et al (1991) found no difference in the 
two groups for hypodontia or supernumerary teeth (Nunn et al., 1991).
1.7.5.7 Dental trauma.
Patients treated for a childhood solid tumour are likely to have experienced several 
operations under general anaesthetic. As this will involved an intubation the patient
may be at an increased risk of dental trauma. Previous studies have stated that 
dental trauma is a known complication of intubation and the most common cause of 
litigation against anaesthesiologists (Hoffmann et al., 2005, Givol et al., 2004, Owen 
and Waddell-Smith, 2000). The incidence of dental trauma has not been investigated 
before in relation to childhood cancer survivors.
1.7.5.8 Craniofacial growth.
Some studies reported disturbances in craniofacial growth and others did not. 
Alpaslan et al (1999) reported no differences in the study group and Michigan normal 
values for craniofacial growth (Alpaslan et al., 1999). Mouth opening and occlusion 
was also examined by Maguire et al (1987) who found no differences between the 
control and study groups (Maguire et al., 1987). Sonis et al (1990) identified study 
groups 1 and 2 (who had received chemotherapy only), to have no significant 
differences in mean cephalometric values compared with normal values (Sonis et al., 
1990). Karsila-Tenovuo et al (2001) looked at disturbances in craniofacial 
morphology in children treated for solid tumours and concluded most deviations in 
craniofacial structures were in children treated for combined chemo and radio 
therapy and these differences were in the vertical plane. This is thought to be due to 
a reduction in cartilage mediated growth. Frequently however they were not clinically 
significant thus not requiring correction, or indeed statistically significant in nature 
(Karsila-Tenovuo et al., 2001).
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1.7.6 Histology.
Maguire et al studied a group of 52 children. On examination 3 children from the 
study group required the removal of teeth, these teeth were subsequently 
histologically analysed. There was an increased prominence of incremental lines 
correlating with periods of intravenous therapy seen in ground tooth section. In 2 
cases, the chemotherapy included a combination of drugs but the third utilised 
vincristine alone. The lines indicate a disturbance in dentinogenesis (Maguire et al., 
1987). Vincristine had been shown to cause incremental lines in rat incisors 
previously (Stene and Koppang, 1976).
1.7.7 Summary of previous literature.
Summarised below in table 1.4 are the main findings from the main studies in the 
available literature investigating the effects on the dentition following malignant 
disease.
Table 1.4 Previous studies investigating the effects of cancer therapy on the 
developing dentition.
Authors, 
year + 
country
Study group 
+ Disease 
type
Control 
group
Main findings
Alpaslan et 
al. 1999.
Turkey.
30 children
4-15 years old 
with
Hodgkins or 
non- Hodgkins 
disease.
20 healthy 
children
 4-15 
years.
Significant differences (p<0.5) in the 
prevalence of enamel hypoplasias, 
discolourations and agenesis in the 
study group. Increased level of plaque in 
the study group.
No differences for gingival index, dental 
caries, craniofacial growth and
microdontia,
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Authors, 
year + 
country
Study group 
+ Disease 
type
Control 
group
Main findings
Kaste et al.
1998
America.
(Memphis).
52 children 
1.9- 19.3 years 
old with a
neurolastoma.
Normal 
population 
but no 
details of 
methods.
Increase in dental abnormalities (71% 
with an abnormality). Including 
microdontia, caries of the primary 
dentition, hypodontia, root stunting and 
enamel hypoplasia.
Maguire et 
al.
1987.
UK
(Newcastle).
52 children
3-22 years old.  
27 leukaemia, 
25 solid 
tumours.
49 
siblings 
ages 2-23 
years.
Increased opacities and hypoplasia in 
the study group. Large number of 
radiographic abnormalities in the study 
group including failed root development, 
microdontia, hypoplasia and missing 
teeth.
No significant differences in dental 
caries, gingivitis and oral hygiene, and 
mouth opening.
Nunn et al.
1991.
UK.
(Newcastle).
52 children
4.75-24.25 
years.
Childhood 
cancer 
(breakdown 
not specified).
41 
siblings
ages 3.4-
20.8 
years.
Statistically significant radiographic 
evidence of enamel hypoplasia, 
taurodontism, microdontia, thin roots 
and root constrictions.
Increased level of enamel opacities, 
enamel hypoplasia but not statistically 
significant.
No significant differences in dental 
caries, and gingival health.
Purdell-
Lewis et al.
1988.
Netherlands.
45 children
7-13 years.
Leukaemia 
and solid 
tumours.
National 
data.
Higher prevalence of dental caries and 
enamel opacities. Radiographic 
evidence of delayed tooth malformation, 
shortened malformed roots and smaller 
crown size.
No difference in oral hygiene.
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1.7.8 Overall conclusions.
The literature documenting the oral effects of cancer therapy is very variable and 
lacks consistency. The population being studied is small the amount of potential 
inconsistencies is high. The few studies that have investigated the oral effects of 
cancer therapy have been carried out over the past 20 years during which time there 
have been many changes and advances in medical technology. For example level of 
caries in the developed countries has fallen (Ferro et al., 2007, Hugoson et al., 2008, 
Downer et al., 2005), there have been advancements in medications and 
standardisation of cancer therapy protocols (CCLG, 2007a). The use of different 
indices between studies makes standards change between studies and therefore 
direct comparisons are often difficult to draw. The level of obvious decay is reported 
in some cases to be above the level in the general population whereas others show 
the caries level to be similar. Reports of the longer term effects on the teeth also 
vary. A number of studies however show consistent evidence of dental anomalies 
particularly hypoplasia, opacities, short thin roots and microdontia. With this level of 
information it is not possible to give consistent advice to parents/guardians and their 
families as to what oral events to expect or what to report following cancer therapy.
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1.8 TREATMENT REGIMES FOR SOLID TUMOURS.   
There are four main treatment modalities for childhood solid tumours. These are 
surgery, chemotherapy, radiotherapy and active observation.
Surgery is used to make the diagnosis, and may be curative itself if an excision 
biopsy is performed. An example would be orchidectomy for a stage I yolk sac 
tumour of the testicle. Definitive surgery to remove all, or the bulk of the tumour 
usually takes place after chemotherapy to reduce the bulk of the tumour.
Cytotoxic chemotherapy is a key component of treatment in many cases of childhood 
malignancy. It is usually used to shrink the primary tumour prior to surgery unless the 
tumour has been completely removed at diagnosis and has no features suggesting 
that it has spread. In the case of the non-Hodgkin’s lymphomas chemotherapy alone 
may be curative without other treatment modalities. It is also usual to give 
chemotherapy after surgery. Chemotherapy may either clear metastatic tumour or 
make it small enough for surgery or radiotherapy to be considered.
Radiotherapy is used in a number of childhood solid tumours, particularly the Ewing’s 
Sarcoma family of tumours (also known as peripheral primitive neuroectodermal 
tumours, or PNETs), rhabdomyosarcomas, neuroblastomas and Wilm’s tumours. 
Radiotherapy is the use of beams of ionising radiation directed at sites of residual 
tumour visible on imaging such as a magnetic resonance scan, or directed at the 
tumour bed where there may be microscopic residual disease. Radiotherapy is given 
to precise anatomical areas and unless the oral cavity was involved in the radiation 
field there would be no effect on dental development.
The effects of radiotherapy on the oral cavity when in the primary radiation field are 
well documented in the literature. Radiotherapy will cause malformation and 
developmental arrest of the growing tooth germs, damage to the salivary glands with 
subsequent hyposalivation leading to radiation induced caries, trismus and the risk of 
developing osteoradionecrosis. (Guggenheimer et al., 1975, Vissink et al., 2003).
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Some tumours may either remain stable in size or spontaneously reduce in size
without any treatment. The most common solid tumour where this may happen is 
stage 4S neuroblastoma occurring in babies less than one year of age. In such cases 
‘treatment’ may simply be active observation (Pinkerton et al., 2004).
More than 80% of children treated with solid tumours will require some form of 
cytotoxic chemotherapy. Children are treated according to the clinical trials and 
guidelines produced by the Children’s Cancer and Leukaemia Group (CCLG). This 
was formed in January 2007 by the merger of the United Kingdom Children’s Cancer 
Study Group and the Medical Research Council Childhood Leukaemia Working 
Party. Some of the clinical trials are international, but within the UK will be 
administered by the CCLG (CCLG, 2007b).
Treatment is given with combinations of cytotoxic drugs which have shown 
synergistic effects against the various tumour types. Conventional chemotherapy is 
usually given at intervals of 21 to 28 days to allow haematological recovery in 
between courses. Some regimes are more intense. For example children with high-
risk neuroblastoma receive eight courses of chemotherapy given at 10 day intervals 
even if there is marrow suppression from the previous course of chemotherapy. 
Haematological toxicity in the form of low platelets and neutrophils is the usual dose 
limiting toxicity that prevents higher doses of chemotherapy being given. Episodes of 
fever in association with neutropenia are common after chemotherapy for childhood 
solid tumours. Less common, but potentially life-threatening, are episodes of 
septicaemia. The oral and gastrointestinal tract mucosa may be damaged directly by 
chemotherapy or secondarily infected by opportunistic organisms in the presence of 
neutropenia. Some chemotherapy drugs may be more likely to cause mucositis 
affecting the oral cavity. This particularly includes anthracyclines and high-dose 
methotrexate (Pinkerton et al., 2004).
High dose chemotherapy and autologous stem cell rescue is used for some solid 
tumours, particularly neuroblastoma. In this case the haematological dose limiting 
toxicity of chemotherapy is overcome by harvesting stem cells from the patient 
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(usually peripheral blood stem cells, occasionally bone marrow) and freezing and 
storing these. The patient is then given a high dose of chemotherapy that ablates the 
bone marrow and the stem cells are then reinfused intravenously. This is the same 
principle as a bone marrow transplant, but because the patient’s own cells are used 
there is no risk of rejection of the cells. In UK practice over the past 20 years total 
body irradiation has not been used in patients with solid tumours undergoing 
autologous stem cell rescue, although it is used in patients who are having bone 
marrow transplants (Pinkerton et al., 2004).
Table 1.5 below shows the classes of cytotoxic drug in common use in the UK to 
treat solid tumours in children (Pinkerton et al., 2004, CCLG, 2007b).
Table 1.5
Drug Notes regarding drug effects.
Alkylating agents
Cyclophosphamide Myelosuppressive and immunosuppressive. 
Ifosphamide Myelosuppressive and immunosuppressive. 
Some patients develop renal damage and in 
extreme cases hypophosphatemic rickets after 
prolonged treatment.
Chlorambucil Myelosuppressive and immunosuppressive.
Melphalan Myelosuppressive and immunosuppressive. Used 
in high dose in paediatric practice where it also 
causes mucositis and marrow ablation.
Busulphan Myelosuppressive and immunosuppressive. Used 
in high-dose in combination with Melphalan 
where it causes mucositis and marrow ablation. 
May cause liver damage.
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Platinum drugs
Cisplatin Some myelosuppression. Causes kidney and 
hearing damage. Patients may have permanently 
low serum magnesium due to a renal tubular 
leak.
Carboplatin More myelosuppressive than cisplatin but effects 
on hearing and kidney function are less at 
conventional doses. May be used in high dose in 
combination with melphalan and etoposide to 
ablate bone marrow. Hearing and kidney damage 
more common in that setting especially if there is 
pre-existing damage.
Antimetabolites
Methotrexate In paediatric solid tumours methotrexate is 
usually used in high doses with folinic acid 
rescue. Mucositis is a very common side effect.
6-Mercaptopurine Immunosuppressant. Affects bone marrow. Used 
for T-cell non-Hodgkin’s lymphoma maintenance 
treatment as per treatment regimes for acute 
lymphoblastic leukaemia.
Cytosine arabinoside Used in high doses in some non-Hodgkin’s 
lymphomas. May cause mucositis.
Anthracyclines
Doxorubicin Principally used in sarcoma treatment as well as 
hepatoblastoma and Wilm’s tumour. Also used in 
non-Hodgkin’s lymphoma. Can cause mucositis 
and myelosuppression. Main late effect is cardiac 
damage which limits total exposure.
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Epirubicin Used up to 2004 for some cases of 
rhabdomyosarcoma. Causes less cardiac 
damage than doxorubicin, but does cause 
myelosuppression and mucositis.
Epipodophyllotoxins
Etoposide A topoisomerase II inhibitor used almost 
ubiquitously in childhood malignancy. Causes 
myelosuppression and in a small number of 
cases mucositis.
Vinca Alkaloids
Vincristine Relatively non myelotoxic and does not cause 
mucositis. Main dose limiting side effect is 
peripheral neuropathy or severe constipation.
Vinblastine Slightly more myelosuppressive than vincristine, 
but no mucositis.
Other
Actinomycin D Antitumour antibiotic. Myelosuppressive and can 
cause acute liver damage. Not associated with 
mucositis.
Prednisolone Steroid used in haematological malignancies 
where is has been shown to have a substantial 
anti-tumour effect.
Procarbazine This is a cytostatic agent with weak monoamine 
oxidase inhibitor activity. The exact mechanism of 
action as an antimitotic is not known. It is used in 
the treatment of Hodgkin’s disease.
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Alkylating agents (predominantly cyclophosphamide, ifosphamide and chlorambucil), 
platinum drugs (cisplatin and carboplatin) and anthracyclines (usually doxorubicin 
and epirubicin in this patient group) are the 3 main different chemotherapy groups 
used. The alkylating agents will cause profound bone marrow suppression and 
consequent neutropenia. Ifosfamide may cause renal tubular damage with leak of 
phosphate and in extreme cases hypophosphatemic rickets. Cisplatin may cause 
renal damage and leak of serum magnesium leading to chronic hypomagnesaemia. 
Carboplatin may have this effect to a lesser extent, but has more bone marrow 
toxicity. As well as causing bone marrow damage the anthracyclines may cause oral 
mucositis (Pinkerton et al., 2004).
Table 1.6 below gives an overview of current treatment, and for treatment regimes 
used in the UK over the past 14 years for the main groups of solid tumours affecting 
children (Pinkerton et al., 2004, CCLG, 2007b).
Table 1.6
Tumour Notes regarding tumour management.
Renal tumours
Wilm’s tumour and clear 
cell sarcoma
Usually diagnostic biopsy, pre-operative 
chemotherapy, surgery and then post operative 
chemotherapy stratified on the response to 
chemotherapy and extent of spread. Radiotherapy 
may be used to the lungs for pulmonary metastases or 
the renal bed if there was local spread.
Treatment duration 8 weeks to 6 months depending on 
stage of disease (up to 12 months prior to 2001). 
Usual chemotherapy vincristine and actinomycin with 
adriamycin for advanced cases. Carboplatin, 
etoposide and cyclophosphamide may be used for 
resistant cases (rare).
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Soft tissue sarcomas
Rhabdomyosarcoma Usually diagnostic biopsy, pre-operative 
chemotherapy, surgery and then post operative 
chemotherapy stratified on the response to 
chemotherapy and extent of spread. Radiotherapy 
may be used to tumour bed if there is microscopic 
residual disease. Usual chemotherapy agents are 
ifosphamide, vincristine and actinomycin and 
sometimes adriamycin. Between 1995 and 2004 more 
advanced cases may also have received carboplatin, 
etoposide and epirubicin. Usual treatment duration 18 
weeks to 30 weeks. HDCSCR used in a small number 
of more advanced cases.
PNET See Ewing’s sarcoma under bone tumours below.
Other soft tissue 
sarcomas
Management as per rhabdomyosarcoma. Tend to be 
more resistant to chemotherapy and local control may 
be more important. Usual chemotherapy agents 
ifosphamide, vincristine and actinomycin.
Lymphomas
Hodgkin’s Lymphoma Usual management is with chemotherapy with 
radiotherapy in up to 20% as well. Treatment lasts 
from 8 weeks to 6 months. Chemotherapy has varied 
over time but usually includes vincristine or vinblastine, 
prednisolone, chlorambucil or cyclophosphamide, 
procarbazine, etoposide, adriamycin and in the past 
bleomycin. In case of recurrence high-dose 
chemotherapy and peripheral blood stem cell rescue 
may be used.
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T-cell Non-Hodgkin’s 
Lymphoma
Management is almost identical to acute lymphoblastic 
leukaemia (common and T-cell) with an intensive 
induction period over 6 months including 
anthracyclines and high-dose methotrexate followed 
by 18 months of maintenance chemotherapy.
B-cell Non-Hodgkin’s 
Lymphoma / leukaemia
Management is with short pulses of intensive 
chemotherapy for up to 8 months. Treatment includes 
alkylating agents, anthracyclines and high-dose 
cytarabine and high-dose methotrexate. Highly 
myelosuppressive and associated with a lot of 
mucositis.
Anaplastic Large Cell 
lymphoma
Management similar to B-cell NHL.
Neuroblastoma
High risk Any tumour with amplification of the MYC-N oncogene, 
or stage III or IV disease in a child over one year of 
age.
Intensive induction with 8 courses of chemotherapy in 
70 days including cisplatin, carboplatin, 
cyclophosphamide and etoposide. Then surgery. Then 
high-dose chemotherapy with peripheral blood stem 
cell rescue (Melphalan alone before 2002, busulphan 
and melphalan or melphalan, carboplatin and 
etoposide since 2002). Then radiotherapy. Then 
treatment with high-dose retinoic acid (since 1999).
Intermediate risk 
(including infants less 
than 1 year)
Conventional chemotherapy cycled every 21 days. 
Included anthracyclines, cyclophosphamide, vincristine 
carboplatin and etoposide.
Stage 4S Observation only unless the disease is causing life-
threatening complications. Usually then responds to 
one or two courses of simple chemotherapy.
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Bone tumours
Osteosarcoma Pre-operative chemotherapy. Surgery to remove the 
tumour (usually endoprosthetic replacement, 
occasionally amputation). Then further post-operative 
chemotherapy. Total duration 6 to 8 months.
Chemotherapy before 2002 was cisplatin and 
doxorubicin. Since 2002 chemotherapy also includes 
high-dose methotrexate. Ifosfamide and etoposide are 
also used where there is a poor response to initial 
chemotherapy. Treatment is frequently associated with 
severe mucositis. 
Ewing’s Sarcoma Intensive induction treatment every 21 days with 
ifosfamide, vincristine, etoposide and doxorubicin for 6 
courses. Then surgery + radiotherapy for local tumour 
control. Then 8 further course of chemotherapy with 
vincristine, actinomycin D and either 
cyclophosphamide or ifosfamide.
Germ Cell Tumours
Various subtypes For those extracranial germ cell tumours requiring 
chemotherapy the usual treatment is a 4 to 6 month
course of carboplatin, etoposide and bleomycin.
Liver tumours
Hepatoblastoma Pre-operative chemotherapy with cisplatin or cisplatin 
and adriamycin. Surgical resection then further 
chemotherapy. Usual treatment duration about 6 
months.
Others Other primary liver tumours are usually managed 
surgically.
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1.9 ORAL HEALTH EPIDEMIOLOGICAL SURVEYS (UK).
The British Society for the Study of Community Dentistry (BASCD) in conjunction with 
the National Health Service have been coordinating a series of epidemiological 
surveys of caries prevalence in the UK since 1985/1986. Each year a different age 
group are investigated for caries experience rotating among 5, 12 and 14-year-olds. 
A sample of at least 250 children are chosen for each district and examined (BASCD, 
2007). In conjunction with these epidemiological studies the Child Dental Health 
Survey (CDHS) is also conducted every 10 years. This started in England and Wales 
in 1973 and included the whole of the UK from 1983 onwards. The survey provides 
information on the dental health of children in the UK (aged 5, 8, 12 and 15), 
measures changes in oral health compared to other surveys and provides 
information on children’s experiences of dental care and their oral hygiene. The 
CDHS specifically investigates obvious decay experience, tooth surface loss (since 
1993 only), enamel opacities (since 1993 and only in 12-year-olds), accidental 
damage, periodontal condition, hygiene behaviour and attitudes to oral health, 
patterns of care and service use, impact of oral health, orthodontic condition and 
social factors in relation to oral health. The data collection occurs by examining 
subjects and using a posted parental questionnaire (Pendry et al., 2004).  Each study 
has strict criteria to follow to ensure consistency across the country and enable valid 
comparisons between studies. 
1.9.1 Dental Caries
The BSACD and CDHS have similar criteria for examination and coding systems for 
the diagnosis of dental caries but with slight differences. For example both studies 
examine the child in a supine position with a daray light placed 1 meter above the 
subject however, the CDHS specifically uses a table whereas the BASCD survey 
uses either a table or reclining sun lounger. In the diagnosis of caries the codes are 
similar except the CDHS 2003 splits code 2 (caries) and 4 (caries and restoration) 
into 2 categories depending on weather the caries is visually cavitated or not.
BASCD describes decay as caries into dentine after visual inspection and does not 
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distinguish between cavitated or uncavitated lesions (BASCD, 1997, Pendry et al., 
2004).  
1.9.2 Enamel Opacities.
Measurement of enamel opacities was introduced into the CDHS in 1993 and were 
measured using the Developmental Defects of Enamel (DDE) Index (Clarkson and 
O'Mullane, 1989). Opacities and hypoplasia’s of teeth can occur as a result of a local 
or systemic upset during the development and calcification of the tooth (Pindborg, 
1982). As chemotherapy is a systemic treatment it is important to consider any role it 
has in enamel defects. As the DDE index is not specific for fluorosis symmetry is also 
observed to allow an estimation of whether the enamel defects can be attributed to 
the level of fluoride ingestion by the individual (Chadwick et al., 2006).
1.10 RESEARCH TECHNIQUES.
1.10.1 Use of questionnaires.
Questionnaires are a simple way of collecting a significant amount of information.
They have to be carefully designed to be clear and specific. Leading and presuming 
questions should be avoided (Reid and Boore, 1987). A closed question involves 
participants indicating a given answer from a list of possible responses. Closed 
questions are quicker to complete and easier to analyse (Williams et al., 2004).
Visual analogue scales can be used and consist of a line 10cm long with a stop at 
both ends. At each end are words descriptive of the maximal and minimal extremes 
of the dimension being measured (Revill et al., 1976). It has been shown that 
respondent error rates can be reduced by employing a horizontal line as apposed to 
a vertical line and by not defining points on the line (McCormack et al., 1988). Open 
questions allow the respondent to decide what level of detail and how to structure the 
answer. These questions can be difficult to analyse due to the variation of replies 
(Reid and Boore, 1987). Questionnaires should have clear instructions on use and be 
easy to read. A pilot version should be carried out first then again if amendments 
were required (Williams et al., 2004).
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1.11 OBJECIVE, HYPOTHESES AND AIMS.
  
1.11.1 Objective.
The project addressed the complete oral health needs of children who have 
experienced a solid tumour during childhood, a subject which was identified as an 
area where more research was needed (NICE, 2005a). 
1.11.2 Hypotheses.
 Individuals who have been treated for solid tumours during childhood will have 
more dental complications in comparison with the general population.
 Individuals who have been treated for solid tumours during childhood will 
require a greater dental input in comparison with the general population.
 The oral health needs of individual groups of solid tumour oncology patients 
will differ according to the type of tumour and therefore the type of treatment 
regime both during and after treatment.
 These patients will have difficulty accessing satisfactory dental care from a 
general dental practitioner.  
 These patients will have limited knowledge of possible future oral health 
complications.
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1.11.3 Aims.
 To identify any patterns of dental care needed in children with solid tumours.
 To investigate if oral health care needs differ according to the specific tumour 
diagnosis or treatment.
 To ascertain if these patients and their parents/guardians understand the need 
for dental input.
 To assess their current dental care arrangements.
 To explore the need for specialist dental input before, during and/or after 
medical treatment.
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2.0.  MATERIALS AND METHODS.
2.1 MATERIALS.
2.1.1 Dental examination (part A).
Equipment:
Chair- sun lounger as used by the BASCD epidemiological studies.
Light- Daray light as used by the BASCD epidemiological studies.
Dental mirror.
WHO 621 C-Type probe. Plastic disposable probes were used with a marked force 
indicator ensuring a constant force of 20-25 grams. There was a 0.5mm spherical tip. 
Banding was present from 3.5-5.5mm, additional marks were at 8.5mm and 11.5mm.
Cotton wool rolls.
Dividers and ruler.
Data collection sheets
Sheet 1- General information sheet (appendix 1).
Sheet 2- Dental charting sheet, BPE and bleeding score (appendix 2).
Sheet 3- Enamel opacities recording sheet (appendix 3).
Information sheets and consent form.
Parental letter explaining the study (appendix 4).
Parents information sheet (appendix 5).
Patient age 16 + information sheet (appendix 6).
Patient age 13-15 information sheet (appendix 7).
Patient age 8-12 information sheet (appendix 8).
Patient age under 8 information sheet (appendix 9).
Consent form (appendix 10).
2.1.2 Questionnaire (part B).
Paper questionnaires were used for collection of data (see Appendix 11 for details).
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2.2 METHODS.
The study took place over 8 months from July 2006-February 2007. Ethical approval 
was obtained from Dudley Primary Care Trust Research Ethics Committee (appendix 
12). The research and development departments of both South Birmingham Primary 
Care Trust (appendix 13) and the Birmingham Children’s Hospital NHS Trust 
(appendix 14) also approved the research protocol and gave permission for the 
research to be carried out. Funding was awarded by the Birmingham Children’s 
Hospital Research Foundation. (appendix 15).
2.2.1 Training of the examiner.
The primary investigator (Alison Hutton) was trained in the dental examination of 
caries by Mrs Pears, Senior Dental Officer, Birmingham Community Dental service, 
using the criteria of caries diagnosis as described by the British Association for the 
Study of Community Dentistry (BASCD, 2005). The primary investigator also worked 
through the 2003 dental heath survey of children and young people computer training 
programme as required by the national examiners in the 2003 Child Dental Health 
Survey. This guidance is similar to the BASCD requirements for dental caries and 
gives further guidance on examination of gingival health and enamel opacities. 
2.2.2 Selection of the study group.
There was a large geographical distribution because Birmingham Children’s Hospital 
is a regional cancer centre covering more that 10% of the population of England and 
Wales. All children who were due to attend the solid tumour follow up clinic at 
Birmingham Children’s Hospital between July 2006 and March 2007 had their 
previous clinic letters reviewed by the primary investigator and the clinic co-ordinator.  
Any children who had finished treatment and had received a course of chemotherapy 
as part of their cancer therapy were invited to take part in the study. Patients with 
tumours of the central nervous system were usually reviewed in a different clinic, but 
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a few who attended on an ad hoc basis were invited to take part in the study. When 
they reached 16 years of age patients were transferred to a transitional clinic at BCH 
prior to moving to adult services at the age of 18. The transitional clinic was held on a 
different day, so again apart from a few patients attending on an ad hoc basis most of
the patients seen in the solid tumour follow-up clinic were 16 years of age or 
younger. The only exclusions were those children who had received radiotherapy to 
the head and neck area specifically. Relapsed patients were included and the total 
time of chemotherapy exposure was used for the calculations.
The patients were invited by a letter (appendix 4) and information sheet sent in the 
post a week before their expected appointment time (appendix 5). Upon arriving at 
the follow up clinic it was confirmed that they wished to participate in the oral health 
study by the clinic co-ordinator. There was an opportunity for the parent/guardian to 
reread the information sheet if they wished to do so and the appropriate aged 
information leaflets were available for the patients if requested.
2.2.3 Patients personal details.
The following personal details were ascertained from the children and their 
parent/guardian participating in the study:
 Hospital number- initially this was taken from the clinician’s clinic sheet and 
confirmed by the family.
 Date of birth.
 Gender.
 Postcode.
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2.2.4 Patients medical details.
The following details were collected from the medical records and confirmed by the 
families during the dental examination:
 Cancer diagnosis.
 Date of diagnosis of cancer.
 Treatment regime.
 Length of time chemotherapy treatment received.
 Time since cancer therapy finished.
2.2.5 Informed consent for the study group.
Informed consent (appendix 10) was obtained from the parents/guardians on 
agreeing to participate in the study. This could be withdrawn at any time by the 
parent or child without explanation throughout the study period. The informed 
consent process involved an explanatory letter through the post followed by the 
opportunity to ask further questions with any member of the research team (doctor, 
investigator, clinic co-ordinator and nurses) at the follow up clinic. Written consent 
was then obtained from every parent/guardian and the child if they wished to sign
before the examination was started.
2.2.6 Control group.
Due to difficulties gaining access to schools and the request at the time of the study 
for positive consent, accessing a healthy age and sex matched population was not 
possible. The control used for this study was national data available in the public 
domain. This included the Child Dental Health Survey 2003 (CDHS) and the British 
Association for the Study of Community Dentistry (BASCD) epidemiological studies.
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2.2.7 Dental examination (part A).
A dental charting, any enamel opacities, fissure sealed, microdont or traumatised 
teeth were recorded on specific data collection sheets. A basic periodontal 
examination and gingival bleeding score were recorded in patients with adult incisors 
and first molars providing they were fully erupted and there were no medical 
conditions predisposing them to infective endocarditis. 
2.2.7.1 Pilot dental examination (part A).
After the first ten patients the results were reviewed by the investigator. Minor 
adjustments to the data collection forms were made to ease recording of information.
These results were later included in the final analysis because the changes made
were minimal.
2.2.8 Development of the questionnaire (part B).
A questionnaire was developed by the author for the parents/guardians to complete 
as the child was undergoing the oral assessment. The questionnaire involved closed 
ended questions of a tick box style to find out specific information, a visual analogue 
scale to give an indication of an opinion and an open ended question at the end, 
providing opportunity for comment. (appendix 12). Questions 2-5 were based on the 
CDHS questions to ascertain social class of the parents (O'Brien, 1994). Many of the 
questions had been taken from an internal audit regarding the provision of dental 
care for patients currently receiving cancer therapy which was previously carried out 
in the same unit by the primary investigator. Those questions had proven to be clear 
and easy for patients to understand.  
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2.2.8.1 Pilot questionnaire study (part B).
The questionnaire was initially piloted to 5 parents and the oncology patient support 
group members, any suggested modifications were made. It was then piloted on the 
first 10 patients recruited for the research and reviewed. These results were included 
in the final analysis as no further modifications were necessary.
2.2.9  Conduct of the study.
2.2.9.1 Location.
The study was carried out at Birmingham Children’s Hospital in the oncology out 
patients department. The dental examination was performed in the oncology day 
case theatre which allowed adequate space for the patient and their accompanying 
adults.
2.2.9.2 Data protection.
Each subject was assigned their own case record folder (CRF) and code number 
therefore ensuring anonymity. Each CRF contained the general information sheet, 
data collection sheets and the questionnaire. The master codes and consent forms 
were locked in an office in the hospital to protect the patient’s identity.
2.2.9.3 Study procedure.
When patients arrived at the clinic they were asked by the clinic co-ordinator if they 
wished to take part in the study. The families had previously received the letter 
through the post explaining the study and therefore had had time to think about 
whether they wished to take part. Both the parent/guardian and child were given the 
opportunity to ask any questions.  On acceptance into the study patients were again 
given the opportunity to ask any questions and shown to the room where the 
research was being carried out. A consent form was completed by the 
parent/guardian. The child was also given the opportunity to sign the form if 
appropriate. If the child had permanent incisor teeth the dentist asked ‘do you carry a 
medical card or has anyone ever advised you to pass on any information to a 
dentist?’ This was the standard question used in the CDHS 2003 (Pendry et al., 
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2004). This was then usually clarified to specifically ask if they suffered from a heart 
murmur, a heart condition or had received any heart surgery. The further clarification 
was used as many children do develop a heart murmur during therapy which later 
resolves. If the answer was yes then further clarification was sought from the medical 
notes to ascertain if antibiotic prophylaxis would be required. If it was thought 
antibiotic prophylaxis was required then the periodontal examination and gingival 
bleeding scores were not carried out for that patient.  The questionnaire was then 
given to the parent/guardian to complete whilst the dental examination was being 
performed. Any queries about the questionnaire were therefore clarified as the form 
was being completed by the parent/guardian.
2.2.9.4 Dental examination.
Patients were asked to sit in the dental chair (sun lounger) which was then fully 
reclined bringing the patients into a supine position. Small children who could not sit 
alone were examined on their parents knee who were sitting in the sun lounger for 
the examination period. The Daray light was switched on and placed a metre above 
the mouth. These criteria are in accordance with the BASCD specifications for having 
a dental examination carried out (BASCD, 1997). The sun lounger was the same one 
that is used for the epidemiological studies for the West Midlands. The investigator 
used a chair without wheels to sit on behind the patients. The CDHS 2003 followed 
similar criteria except a flat table was used for the patient to lie on for the dental 
examination (Pendry et al., 2004).
The mouth was examined visually using only using a mouth mirror. A probe was 
used only to remove any debris on the surface of the tooth which impaired a direct 
view of the tooth. Each tooth and individual tooth surfaces were examined in a 
standard order (upper left, upper right, lower left, lower right, distal, occlusal, mesial, 
buccal and lingual) The teeth were not brushed beforehand. A tooth was deemed to 
be present if any part of it was observed. Surfaces that could not be fully examined,
for example those with orthodontic bands, were recorded as “excluded” (Pendry et 
al., 2004, BASCD, 1997).
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Decayed, missing, and filled teeth and surfaces were recorded on a dental 
examination chart. Orthodontic extractions were not included in the missing tooth 
data.  The coding used was as follows:
0= sound
1= arrested caries
2= decayed
3= unrestorable
4= filled and decayed
5= filled with no decay
R= filed but needs replacing
6= extracted due to caries
7= extracted due to orthodontic reasons
8= unerupted
9= excluded 
$- sealant
N= sealant restoration
T= traumatised
C= crown/ advanced restoration
(BASCD, 1997)
Any obviously microdont teeth (in the primary investigators clinical opinion) were also 
recorded. A specific criteria was not used for this as there were none available but to 
be observed as microdont the teeth were at least under 50% of the expected size.
The basic periodontal examination (BPE) was carried out using a world health 
organisation 621 probe in children with all central incisors and first molar teeth who 
had not answered yes to the question regarding potential antibiotic prophylaxis. 
Scores of 0= healthy, 1= bleeding on probing, 2= calculus/possible restoration 
margin, 3= shallow pockets 4-5mm and 4= deeper pockets >5.5mm were used. All 
teeth were examined by placing the probe in the distal part of the sulcus and running 
the probe around the margin to the mesial surface on the buccal and lingual sides of 
each tooth. Teeth recorded for the BPE were the four first molars and central incisors 
in each quadrant only. All  teeth were then examined for any areas of bleeding on 
probing which was recorded site by site (distal, buccal, mesial, lingual) on the data 
sheets where code 0= no bleeding from the gingival sulcus, code 1= bleeding from 
the gingival sulcus and code 9= assessment cannot be made.  This method of 
recording the data allowed further analysis in accordance with the 2003 CDHS
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criteria for measuring gingivitis as they do for 15-year-old patients (Pendry et al., 
2004).
A subject was recorded as having gingivitis if there was a single site or more on any 
tooth (mesial, distal, buccal, lingual) which bled on probing. Gingival bleeding is a 
marker of gingivitis as defined in the Child Dental Health Survey 2003.  The Child 
Dental Health Survey recorded gingivitis (as bleeding on probing) in 15-year-olds 
only. The criteria used included 6 teeth; the first molars in each quadrant and the 
upper right central incisor and the lower left central incisor. The upper teeth were 
recorded by looking at the mesial, distal and buccal surfaces only and the lower teeth 
had the distal, mesial and lingual surfaces recorded only. If there was bleeding in any 
of the specified sites the subject was considered to have evidence of gingivitis
(Pendry et al., 2004).  
When recording enamel opacities, if the surfaces of the teeth were obscured with 
plaque this was wiped away using a cotton wool roll. The teeth were examined whilst 
the patient was still in the sun lounger with the light on.  The teeth examined were the 
upper eight front teeth ( 4321|1234) The labial (incisors and canines) or buccal (pre 
molars) surfaces were examined only. The criteria and descriptions are as below:
 Normal: Any single defect less than 1mm was classed as normal.
 Demarcated opacity: A defect involving an alteration in the translucency of the 
enamel, variable in degree. The defective enamel is of normal thickness with a 
smooth surface.  It has a distinct and clear boundary with adjacent normal enamel 
and can be white, cream, yellow or brown in colour.
 Diffuse opacity: A defect involving an alteration in the translucency of the enamel, 
variable in degree. The defective enamel is normal in thickness and at eruption 
has a smooth surface and is white. It can have linear, patchy or confluent 
distribution but there is no clear boundary with the adjacent normal enamel.
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Lines: Distinctive white lines of opacity which follow the lines of development of the 
teeth. Confluent adjacent lines may occur.
 Patchy: Irregular, cloudy areas of opacity lacking well defined margins.
 Confluent: Diffuse patchiness has merged into a chalky white area extending from 
mesial to distal margins which can cover the entire surface or be confined to a 
localised area of the tooth surface.
 Hypoplasia: A defect involving the surface of the enamel and associated with a 
reduced localised thickness of enamel. It can occur in the form of (a) pits; single 
or multiple, shallow or deep, scattered or in rows of pits arranged horizontally 
across the tooth surface. (b) grooves; single or multiple, narrow or wide (max 
2mm) or partial or complete absence of enamel over a considerable area of 
dentine. Enamel of reduced thickness may be translucent or opaque.
TYPE OF DEFECT:
Code 0- normal
Code 1- demarcated opacity
Code 2- diffuse opacity
Code 3- hypoplasia
Code 4- demarcated+ diffuse
Code 5- demarcated +hypoplasia
Code 6- diffuse+ hypoplasia
Code 7- all 3 defects
Code 8- other defects
Code 9- Assessment cannot be made
EXTENT OF DEFECT:
Code 0- normal 
Code 1- less than 1/3
Code 2- at least 1/3-2/3
Code 3- at least 2/3
Code 9- assessment cannot be made
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If more than two thirds of the tooth was decayed or fractured it was not used for 
recording in accordance with the 2003 CDHS regulations for recording enamel 
opacities (Pendry et al., 2004).
SYMMETRY OF DIFFUSE DEFECTS:
Code-0= no diffuse defects
Code 1= diffuse defects but not symmetrical
Code 2= diffuse defects symmetrical
(Pendry et al., 2004).
2.2.9.5 Repeat examinations.
Due to the limited staff available at the time of data collection the results could not be 
verified by another examiner at that dental visit. By the nature of the ‘follow up’ clinic 
patients were only attending every 6 months or yearly and therefore the investigator 
was unable to examine the patients on another separate occasion to improve validity 
of the results.
2.2.9.6 Questionnaire completion.
The questionnaire was always completed by the parent/guardian whilst the child was 
undergoing the dental examination. Any queries that arose were answered by the 
investigator or dental nurse. Non English speaking parents/guardians were always 
accompanied by an interpreter. The interpreter was present for both the medical and 
dental appointments that day. The questionnaire was collected at the end of the 
examination and placed in the CRF with the other data sheets.
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2.2.10 Investigator interventions.
If any subject was identified to have a need for dental treatment the investigator 
informed the subject and their parent/guardian. If the subject had a dentist, the 
dentist was informed of the treatment need and the subject asked to make an 
appointment with the dentist. If the child was not registered with a dentist they were 
offered treatment by the Birmingham Children’s Hospital dental team or referred to 
their nearest community dental clinic. The opportunity was given to all patients and 
their families to discuss any aspect of the study or their dental examination further at 
the end of the appointment.
2.2.11 Review of the study.
After a period of one month the study was reviewed by all authors. Minor changes 
were made to the practicalities running of the research data collection procedures
during the clinic. These did not affect the analysis of results.
2.2.12 Tabulation of the data.
The results were tabulated in Microsoft XP Excel spreadsheets. The data was 
entered twice on separate occasions and then compared and corrected for any
discrepancies before data analysis began. Any inconsistencies were highlighted and 
checked with the original data sheets.
Once all the data had been collected, the details of which chemotherapeutic agents 
had been used for each subject were added to the identification code by the research 
supervisor. This was done blind of any results. The details were then added to the 
main data sheet according to their subject number.
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2.2.13 Analysis of results.
Analysis of the study group as a whole was undertaken initially. Separate spread
sheets were then created of individual groups for analysis. These included separate 
sheets for those who were 5,8,12 and 15 years old on the day of examination, the 
tumour groups according to diagnosis and the groups according to type of 
chemotherapy regime received. The data analysis was largely descriptive given the 
small sample size and huge number of variables. Where appropriate a chi squared 
test and the Fishers exact test were used to investigate the relationship between two 
specific aspects. The Excel programme was used for the calculations  
2.2.13.1 Caries analysis.
The experience of dental experience was described using the decayed, missing and 
filled tooth index (DMFT) (Klein et al., 1938). The ‘DMFT’ index is used for the 
secondary (adult) dentition. The ‘dmft’ index is used for teeth in the primary
(deciduous). A child who was in the mixed dentition would therefore have had two 
separate values for both the DMFT (adult) and dmft (deciduous). 
2.2.13.2 Opacities analysis.
The ingestion of fluoride either by water fluoridation or fluoride tablets is known to be 
associated with an increased incidence of enamel opacities (Wong et al., 2006, 
Cochran et al., 2004, Tabari et al., 2000). Because many of the study population live 
in fluoridated areas of the country this was investigated further.  Therefore in the 
analysis of the opacities data references are made to the water supply and if it is 
fluoridated or not. This was identified from the postcode. It should be remembered 
the effect of fluoride on the dentition occurs at an age when the tooth is forming and 
calcifying only (Hong et al., 2006). For the purposes of the study it was assumed that 
the patient had lived at that post code all their life because more in depth analysis 
was beyond the scope of this thesis. In analysis of the results this assumption should 
be considered. 
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2.2.13.3 Questionnaire analysis.
In analysis of the questionnaire where the visual analogue scale was used, any tick, 
cross or circling of the word very ‘important’ was considered to be 10cm on the visual 
analogue scale.
2.2.13.4 Social class information.
The National Statistics Socio-Economic Classification (NS-SEC) was introduced in 
2001 to replace the previous Registrar General’s Social Class and Socioeconomic 
Grouping (1980). The new classification was derived after concern about the 
previous classification system having conceptual and operational deficiencies. These 
were first raised and reviewed in 1994. The new model is based on a wide
conceptual model also used by many other countries. It is a hierarchical system and 
can be collapsed into several variables for use in policy modelling and research. The 
NS-SEC system includes 3 tiers of coding described as the eight category, five 
category and three category versions. The “never worked” and “long term 
unemployed” classification group can be added or removed from each version 
depending on the particular analysis required. It is described as being more flexible 
and has specific rules for the inclusion of un-employed people, provides improved 
classifications for women’s employment positions and reflects current thinking by not 
splitting work into manual and non manual. It has been tested and validated (Rose 
and O'Reilly, 1998).
The new classification has 8 main categories: 
1= Higher managerial and professional.
2= Lower managerial and professional.
3= Intermediate occupations.
4= Small employers and own account workers.
5= Lower supervisory and technical occupations.
6= Semi-routine occupations.
7= Routine occupations.
8= Never worked and long term unemployed.
(ONS, 2005, Pendry et al., 2004).
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The coding used in the Children’s Dental Health Survey 2003 is the modified three 
class version as above linking 1+2 as managerial and professional, 3+4 as 
intermediate and 5+6+7 as routine and manual with separate “never worked” and 
“long term unemployed” categories (Pendry et al., 2004). The data was analysed 
using both the NS-SEC and Registrar General’s coding system.
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3.0 RESULTS AND ANALYSIS.
3.1 RESULTS AND ANALYSIS DENTAL EXAMINATION (PART A).
3.1.1 Demographics of the study group. 
Out of the 125 patients who were invited to participate in the study 5 patients were 
not included. Of the 5 patients not participating 2 refused to consent, 1 family left 
before the examination forgetting to visit the dentist after their medical consultation, 1 
could not co-operate for an examination due to behavioural difficulties and 1 had time 
constraints on the day preventing a dental examination. The study group therefore 
consisted of 120 patients (69 males and 51 females) attending the oncology follow up 
clinic between July 2006 and February 2007 at Birmingham Children’s Hospital. All 
children selected had been previously diagnosed with a solid tumour and as part of 
their medical treatment had undergone a course of chemotherapy.
3.1.1.1 Geographic distribution of the study group.
Sixty six percent of the study patients were from the West Midlands (including 
Wolverhampton, Dudley, Walsall, Sandwell, City of Birmingham, Solihull, City of 
Coventry) and the remaining 34% from the surrounding areas (Warwickshire, 
Worcestershire, Staffordshire, Hertfordshire, Northamptonshire, Derbyshire, 
Shropshire, and Powys). All the above areas were supplied with water by either the 
Severn Trent Water Board or the South Staffordshire Water Board. The Severn Trent 
water is artificially fluoridated and the South Staffordshire water is not artificially 
fluoridated.
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Figure 3.1
Number of patients living in an area with fluoridated water  
n=120.
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 (26.7%)
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3.1.2 Composition of the study group.
3.1.2.1 The medical diagnosis of the group.
Table 3.1
Medical Diagnosis Number (%)
Wilm’s Tumour 29 (24.2)
Rhabdomyosarcoma 10  (8.3)
Hodgkin’s Lymphoma 14 (11.7)
Non-Hodgkin’s Lymphoma 10 (8.3)
Neuroblastoma 21 (17.5)
Other 36 (30.0)
Total 120
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The other diagnoses were as follows (there being one of each diagnosis unless 
otherwise stated): hepatoblastoma (4), pineoblastoma, osteosarcoma (4), giant cell 
fibroblastoma, histiocytosis (2), Ewings sarcoma/ peripheral primitive 
neuorectodermal tumour (PNET), synovial sarcoma, Burkitt’s lymphoma/leukaemia,
germ cell tumour, fibrosarcoma, primitive neuroectodermal tumour, WAGR syndrome
(Wilm’s tumour, aniridia, genitourinary anomalies and mental retardation),
retroperitoneal inflammatory myofibroblastic tumour, stage II sacrococcygeal yolk sac 
tumour, clear cell sarcoma (4), ganglioneoroblastoma (2), T-cell leukaemia and 
lymphoma, glioblastoma, optic chiasm glioma, hepatic sarcoma, medulloblastoma,
synovial sarcoma, anaplastic large cell lymphoma, pleuropulmonary blastoma of 
hemi thorax.
3.1.2.2 The age of the study group at diagnosis and dental examination.
Figures 3.2 and 3.3 demonstrate the different ages of the study population at 
diagnosis of cancer and at the time of the dental examination. The diagnostic age 
group is positively skewed towards those below 5 years old. The age at examination 
is varied with peaks at 7, 13 and 15 years old.
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3.1.2.3 Treatment regime the patient had experienced.
All children must have experienced a course of chemotherapy to be included in the 
study.  The length of time each child was subjected to chemotherapy varied within 
the study group. Figure 3.4 represents these different time periods. 
Figure 3.4
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The range in the length of time patients receive chemotherapy for was 1 month to 4.5 
years, the mean was 8.19 months (S.D=7.39) the median was 6 months.
3.1.2.4 Type of chemotherapy received by the patient.
The study group received different forms and combinations of chemotherapy 
treatment. There were four main groups of agents used for the patients in the study. 
These were:
 High dose chemotherapy with stem cell rescue (HDCSCR).
 Anthracycline drugs.
 Alkylating agents.
 Platinum drugs.
There were however, overlapping regimes as illustrated in the Venn diagram in figure 
3.5.
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Figure 3.5 Illustration of the different chemotherapy regimes within the study group.
Given the multiple number of treatment regimes stratification into individual treatment 
groups was not possible because the therapeutic combinations were complex. The
individuals not accounted for in the above diagram were given less toxic                        
chemotherapeutic drug regimes.
3.1.2.5 Time since therapy.
The amount of time since the patients finished their active treatment and started 
attending the ‘follow up’ clinic was recorded and shown in figure 3.6. N=120, mean 
51.97 (S.D 40.3) months.
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0
10
20
30
40
50
60
Number of 
subjects
<1 1 to 5 >5
Years
Amount of time elapsed since completion of chemotherapy.
The follow up period varied from those who had recently finished chemotherapy 
treatment to those who had finished medical treatment 12-14 years previously. Those 
who had finished medical treatment more recently are monitored more frequently and 
therefore could account for the increased number of patients under the 5 year time 
period.
The study group was made up of children in the deciduous, mixed and adult 
dentition. Categories with the stages as illustrated in figure 3.7. Data were later 
grouped into age, medical diagnosis, and type of chemotherapy for further analysis.
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Figure 3.7
Different dentitions of the study group n=120.
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3.1.2.6 Composition of the sub-groups; post stratification.
The diagnostic and treatment groups are described below in tables 3.2-3.5.
Table 3.2. Number, gender and age of the diagnostic stratifications.
Group Number of 
patients
Male/female Mean age in years (age 
range).
Hodgkin’s 
Lymphoma
14 13/1 12.9  (5-17)
Neuroblastoma 21 11/10 6.7    (1-15)
Non-Hodgkin’s 
Lymphoma
10 8/2 12.5  (7-15)
Rhabdomyosarcoma 10 6/4 10.1  (4-15)
Wilm’s tumour 29 15/14 7.8    (3-16)
Other 36 16/20 10.7  (1-17)
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Table 3.3. Length of, and amount of time since, chemotherapy in the diagnostic 
groups.
Group Mean time period of 
chemotherapy treatment in 
months (range).
Mean amount of time since 
completion of chemotherapy 
treatment in months (range).
Hodgkin’s 
Lymphoma
6.2   (2-12) 40.1  (7-82)
Neuroblastoma 6.1   (1-18) 55.5  (8-177)
Non-Hodgkin’s 
Lymphoma
6.8   (3-24) 67.1  (17-119)
Rhabdomyosarcoma 8.9   (3-24) 73.3  (29-151)
Wilm’s tumour 7.8   (1-30) 58.1  (1-170)
Other 10.4 (1-54) 41.4  (1-130)
The smallest categories were the rhabdomyosarcoma and non-Hodgkin’s lymphoma 
groups with the largest being the mixed tumour group. Data demonstrated a wide 
range of ages and treatment times within each group.
Table 3.4. Number, gender and age of the treatment stratification groups.
Group Number of 
patients
Male/Female Mean age in years 
(range)
HDCSCR 14 7/7 7.07   (1-15)
Alkylating agents 
and no HDCSCR
66 45/21 10.47 (1-17)
Anthracyclines and 
no HDCSCR
66 41/25 10.88 (3-17)
Platinum drugs and 
no HDCSCR
43 16/14 9.40   (2-17)
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Table 3.5 Length of, and amount of time since completion of chemotherapy treatment 
in the treatment stratification groups.
Group Mean time period of 
chemotherapy treatment in 
months (range)
Mean amount of time since 
completion of chemotherapy 
in months (range)
HDCSCR 6.04 (2.5-12) 58.93 (8-177)
Alkylating agents 
and no HDCSCR
8.35 (2-31) 46.45 (1-151)
Anthracyclines 
and no HDCSCR
8.96 (2-31) 48.88 (1-144)
Platinum drugs 
and no HDCSCR
8.52 (2-130) 49.47 (2-130)
3.1.3 Experience of dental caries.
The experience of dental caries was described using the codes as explained in the 
methodology. Overall 67 (55.8%) patients in the study population were caries free
with the remaining 53 (44.2%) experiencing obvious decay at the time of the dental 
examination. Table 3.6 illustrates the mean DMFT, dmft of the study group indicating 
higher caries levels in the primary dentition.
Table 3.6 DMFT, dmft of the study population.
Mean number of carious teeth 
+/- S.D.
DMFT 0.56 +/- 1.18
dmft 0.84 +/- 1.99
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3.1.3.1 Results by direct comparison with the 2003 Child Dental Health Survey.
The 2003 Child Dental Health Survey investigated the caries experience of 5,8,12 
and 15-year-olds. To allow direct comparisons the data for those age groups were
analysed separately. It is important to remember the small sample sizes when 
interpreting the data and drawing conclusions from the data.
Figure 3.8 demonstrates the 8 year old study population has a higher dmft value by
comparison with the CDHS 2003 (Pitts and Harker, 2005).
Figure 3.8
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Table 3.7 compares the DMFT study data for 8,12 and 15-year-olds with the 2003 
Child Dental Health Survey (Pitts and Harker, 2005).
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Table 3.7 Comparison of DMFT values and percentage without any obvious caries 
experience for 8,12 and 15-year-olds with the study and national data (2003 CDHS)
(Pitts and Harker, 2005).
Obvious decay experience 
(mean no teeth)
Percentage without 
obvious caries experience
(%)
8 yr study group (n=5) 0.2 80.0
8 yr UK 2003 0.3 86.0
8 yr England 2003 0.3 83.0
8 yr West Midlands 2003 0.3 83.0
12 yr study group (n=7) 0.3 85.7
12 yr UK 2003 1.1 66.0
12 yr England 2003 1.0 59.0
12 yr West Midlands 2003 0.9 61.0
15 yr study group (n-11) 2.0 72.7
15 yr UK 2003 2.0 51.0
15 yr England 2003 1.8 45.0
15 yr West Midlands 2003 1.9 47.0
Despite there being low numbers in each group the figures show the only groups to 
be dissimilar to the Child Dental Health Survey group are the 8-year-old primary 
dentition data showing a higher dmft and the 12-year-old study group showing a 
lower DMFT. As the study groups are so small no definitive conclusions can be 
drawn. 
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3.1.3.2 Dental caries experience of treatment regime groups.
When the study data was stratified into medical chemotherapy treatment groups the 
results are represented in figure 3.9.
Figure 3.9
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The high dose chemotherapy and stem cell rescue (HDCSCR) group demonstrated
considerably higher dmft values by comparison with the other groups. This group 
comprised patients suffering mainly from neuroblastoma and were young at 
diagnosis. The DMFT values are similar between the different treatment groups.
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3.1.3.3 Dental caries experience of the tumour diagnostic groups.
Figure 3.9 also illustrates differences in DMFT, dmft values within the different 
diagnostic groups.
Figure 3.10
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The neuroblastoma group have the highest decay experience in the primary 
dentition, as shown by the number of teeth affected. The neuroblastoma group will 
have received more significant treatment as many are included in the HDCSCR 
treatment group (figure 3.9). The rhabdomyosarcoma group also show an increased 
level of decay experience in the primary dentition.  
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3.1.3.4 Summary of dental caries experience.
 55.8% of the study group had no decay or treated decay present on 
examination.
 42.2% of the study group had experienced decay in one or more teeth.
 30.8% of the study group had untreated tooth decay in one or more teeth.
 18.3% of the study group had untreated primary tooth decay in one or more 
teeth.
 18.3% of the study group had untreated secondary tooth decay in one or more 
teeth.
 The neuroblastoma and HDCSCR group showed higher levels of primary 
dental caries by comparison with the other tumour diagnostic and treatment 
groups and the general population.
3.1.4 Enamel opacities.
Eighty patients had their dental enamel opacities recorded in the 8 upper anterior 
teeth (upper right 4,3,2,1 and upper left 4,3,2,1).  Opacities were found in 50 (62.5%) 
patients from the study group.
Because not all patients had all 8 front teeth present at the time of examination,
opacities were recorded in 145 teeth (27.9%) out of a possible 519 teeth which were 
erupted at the time of examination.
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Figure 3.11 and 3.12 illustrates examples of “diffuse” and “demarcated” types of 
enamel opacities.
Figure 3.11 diffuse lesions on the central incisor teeth.
a) b)
Figure 3.12 (a) A picture of demarcated lesions of the anterior teeth and (b) a 
demarcated lesion of the upper left central incisor.
a) b)
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The proportion of patients with opacities and the type of opacity within the study 
group are show in table 3.8. It is worth noting some patients will have demonstrated 
more than one type of opacity on their front teeth.
Table 3.8 Proportion of patients with opacities and the type of opacity within the study 
group.
Opacity Code Opacity type Number of 
teeth with that 
code
Number of 
patients 
with that 
code (%) 
n=80
0 No opacity 372 50 (62.5)
1 Demarcated 16 12 (15.0)
2 Diffuse 120 42 (52.5)
3 Hypoplasia 0 0    (0.0)
4 Demarcated and diffuse 4 3    (3.8)
5 Demarcated and hypoplasia 3 3    (3.8)
8 Other defects 2 1    (1.3)
9 No assessment made 4 1    (1.3)
Table 3.9 Extent of opacities within the study group.
Opacity extent 
code
Extent Number of 
teeth
Number of 
patients 
n=80 (%)
1 Less that 1/3 115 50 (62.5)
2 At least 1/3-2/3 23 15 (18.8)
3 At least 2/3 7 4    (5.0)
9 No assessment made 4 1    (1.3)
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Table 3.10 Symmetry of opacities within the study group.
Opacity symmetry 
code
Symmetry of diffuse defects Number of 
teeth
Number of 
patients 
n=80 (%)
1 Diffuse defects but not 
symmetrical
97
38 (47.5)
2 Diffuse defects symmetrical 27 13 (16.3)
3.1.4.1 Results for opacities by direct comparison with the 2003 Child Dental 
Health Survey.
In the Child Dental Health Survey only 12-year-olds were examined for enamel 
opacities. 35% in England had one or more opacity (Chadwick and Pendry, 2004). 
From the study data in 12 years olds, 3 (42.9% n=7) had an opacity.  As opacities are 
stable and do not change over time this figure can also be compared with the whole 
study group percentage of 62.5% patients with an opacity on the front teeth. 
Figure 3.13 shows enamel opacity results from the dental Health Survey in 12-year-
olds (Chadwick and Pendry, 2004) compared with the 12-year-old study data and the 
study data as a group.
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Figure 3.13
Level of different types of enamel opacities within the study 
data, study 12-year-olds and the national data.
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Table 3.11. Extent of lesions on teeth in the 2003 Child Dental Health Survey and the 
study data.
Demarcated 
2003 CDHS
data (%)
Diffuse 
2003 
CDHS 
data 
(%)
Demarcated 
and diffuse 
2003 CDHS
data (%)
Demarcated 
study data 
number (%)
(n=16)
Diffuse
study 
data
number
(%) 
(n=120)
Demarcated 
and diffuse 
study data
number (%) 
(n=4)
 <1/3 92 59 32 12 (75.0) 96 
(80.0)
4 (100)
1/3-
2/3
6 28 54  3 (18.8)  20 
(16.7)
0 (0.0)
>2/3 2 11 13  1 (6.3)  4 (3.3)  0 (0.0)
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66% of diffuse lesions in the Child Dental Health Survey were symmetrical.  21.8% of 
the study group diffuse lesions were symmetrical. 
Figure 3.13 and table 3.11 compare the study cohort as a population, the study 12-
year-old group specifically and the national data from the 2003 CDHS. The 12-year-
olds in the study group do show a higher level of demarcated lesions in comparison 
with the 2003 CDHS, however if the whole study population is considered the overall 
level of demarcated lesions are similar to the 2003 CDHS. The largest difference 
within the study population concerned the diffuse lesions. The study data do show an 
increased level.
3.1.4.2 Opacities present within each tumour group.
Table 3.12 Opacities present within each tumour group.
Group Number of 
patients
tested for 
opacities
(number of
teeth 
tested)
Number (%) 
of teeth 
observed 
with 
opacities
Of those 
with 
opacities 
number(%) 
of
demarcated
opacities
Of those 
with 
opacities 
observed  
number 
(%) of 
diffuse
opacities
number
(%) of  
other 
opacities 
Hodgkin’s
Lymphoma
12 (92.0) 39 (42.0)  4 (10.3)  34 (87.1)  1 (2.6) 
demarcated 
and diffuse
Neuroblastoma 11 (58.0)  17 (29.3)  5 (29.4) 11 (64.7)  1 (5.9)
demarcated 
and 
hypoplasia
Non-Hodgkin’s
Lymphoma
9 (62.0)  12 (19.4)  5 (42.0) 6 (50.0) 1 (8.3)
demarcated 
and diffuse
Rhabdomyosarcoma 7 (41.0)  14 (35.9)  1 (6. 7) 12 (80.0)  1 (6.7)
demarcated 
and 
hypoplasia
Wilm’s tumour 14 (80.0) 29 (36.2)  0 (0.0)  25 (86.2)  4 (13.8)
demarcated 
and diffuse 
and other 
defects
Other 27 (184.0) 34 (17.7)  1 (2.9)  32 (94.1)  1 (2.9)
demarcated 
and 
hypoplasia
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3.1.4.3 Opacities present within each different treatment regime group.
Table 3.13 Opacities present within each different treatment regime group.
Group Number of 
patients
tested for 
opacities
(number 
of teeth 
tested)
Number 
(%) teeth 
observed 
with 
opacities
Of those 
with 
opacities 
number (%) 
demarcated 
Of those 
with 
opacities 
observed
number
(%)
diffuse
Number 
(%)
other 
opacities
HDCSCR 8 (42.0)  14 (33.3) 5 (35.7)  8 (57.1) 1 (7.1) 
demarcated  
+ hypoplastic
Alkylating agents 
and no HDCSCR
47 (306.0)  89 (29.1) 11 (12.3) 73 (82.0) 9 (10.1) 
mixture of 
codes 
4,5,8,9
Anthracyclines 
and no HDCSCR
53 (329.0) 91 (27.7)  0 (0.0)  76 
(83.5)
 5 (5.5)
mixture of 
codes 4,5,8
Platinum drugs 
and no HDCSCR
20 (133.0)  21 (15.8)  0 (0.0) 21 
(100.0)
0 (0.0)
Tables 3.12 and 3.13 demonstrate the level of opacities within each data analysis 
sub group. No significant trends were identified within the data.
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3.1.4.4 Correlation between enamel opacities and the level of water fluoridation.
Table 3.14 Comparison between the occurrence of opacities and the level of 
fluoridation of the water supply.
Fluoridated area Non fluoridated area
Opacities 38 patients 12 patients
No Opacities 23 patients 8 patients
Table 3.15 Comparison between the type of enamel opacity and the level of water 
fluoridation.
Fluoridated area Non fluoridated area
demarcated  opacities 8 patients 4 patients
diffuse opacities 33 patients 9 patients
Using Chi squared testing there were no significant differences between fluoridated 
and non-fluoridated areas with respect to enamel opacities (P=NS).
3.1.4.5 Summary of opacities.
 Opacities were recorded in 62.5% of those tested from the study group. 
 The commonest defect was a diffuse defect, shown in 52.5% of patients with 
an opacity. This was a higher incidence by comparison with the 2003 CDHS 
with 16.0% of opacities being diffuse defects.
 There were no significant differences between the diagnostic and treatment 
groups for prevalence of opacities.
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3.1.5 Gingival health.
Gingival health was examined in 78 patients but was not assessed in those patients
in the deciduous dentition and early mixed dentition (n=37) and those who were at 
risk of infective endocarditis (n=5). 
Figure 3.14
Proportion of those examined for gingivitis with 
gingivitis present and those with healthy gingivae.
 Gingivitis
31 (40%)
No gingivitis
47 (60%)
2.53%, of sites were affected by gingivitis, in the mouth overall (range 1 site to all 
sites).
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Figure 3.15
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Figure 3.15 illustrated that the majority of patients (83.0%) had 1-10 sites in the 
mouth affected by gingivitis.  No child was shown to have periodontal disease as all 
BPE scores were 0,1 or 2.
3.1.5.1 Gingival health by comparison with the 2003 Child Dental Health Survey
cohort.
The 2003 CDHS found 45% of 15-year-olds in England to have evidence of gingivitis
by assessment of bleeding on probing the gingivae (White and Lader, 2004). Of the 
study population of 15-year-olds, 6 (54.5% n=11) patients were found to have 
evidence of gingivitis. Figure 3.16 shows the number of patients with gingivitis in the 
study group and 15-year-olds and compares them to the England and UK 2003 
CDHS data (White and Lader, 2004).
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The specific teeth affected are illustrated in table 3.16.
Table 3.16 Areas of gingivitis in the mouth for 15-year-olds.
                   Percentage of 15-year-olds with gingivitis in the specified tooth
upper 
right 6
Upper 
right 1
Upper 
left 6
lower 
left 6
Lower 
left 1
lower 
right 6
any 
tooth
gingivitis 
n=11
18.2 27.3 18.2 18.2 18.2 18.2 54.5 
2003 
CDHS 
(UK)
15.0 13.0 15.0 21.0 13.0 23.0 43.0
The percentage of 15-year-olds with gingivitis stratified by gender in the study and 
general populations are illustrated in table 3.17.
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Table 3.17 Gingivitis by gender in 15-year-olds.
Percentage of boys 
(n=11)
Percentage of girls 
(n=11)
gingivitis (girls n=3, boys 
n=8)
62.5 33.3
2003 CDHS (UK) 39.0 46.0
More girls were found to have gingivitis than boys in the 2003 CDHS (White and 
Lader, 2004). The 2003 CDHS did recognise that this was the opposite of the 
findings when gingivitis was recorded by visual examination only. In the visual 
examination the gingivae were looked at and described as either healthy or not 
healthy (red inflammation present on the buccal or lingual surfaces of each tooth). 
The teeth were divided into sextants for this recording. When recorded in this manner
56% of male 15-year-olds had signs of gingivitis and 48% of female 15-year-olds had 
signs of gingivitis (White and Lader, 2004). Gingivitis was not recorded in this manner 
in this thesis. However more boys demonstrated gingivitis than girls.
3.1.5.2 Periodontal condition by diagnostic group.
Table 3.18 Gingival health of the different diagnostic groups. (BOP= bleeding on 
probing).
Group Number of 
patients
tested
Number of 
patients with 
BOP (%)
Average no. of sites 
BOP in those with 
BOP
Hodgkin’s
Lymphoma
12  7 (58.3) 8.14
Neuroblastoma 11  4 (36.4) 5.75
Non-Hodgkin’s
Lymphoma
10  8 (80.0) 5.12
Rhabdomyosarcoma 7 7 (100.0) 7.00
Wilm’s tumour 11  5 (45.5) 5.80
Other 27  16 (59.2) 11.56
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3.1.5.3 Gingival health by treatment group.
Table 3.19 Gingival health of the treatment groups. (BOP= bleeding on probing).
Group Number of 
patients
tested
Number  of 
patients with 
BOP (%)
Average no. of sites 
BOP in those with 
BOP
HDCSCR 8 3 (37.5) 1.64
Alkylating agents 
and no HDCSCR
48  35 (72.9) 6.52
Anthracyclines and 
no HDCSCR
48  34 (70.8) 4.60
Platinum drugs and 
no HDCSCR
30  11 (36.7) 7.30
Tables 3.18 and 3.19 show no specific trends in any of the treatment and diagnostic 
groups. One patient’s parent however did mention in the “comments” section that 
their child “has major bleeding of his gums and they are so sore if we brush them 
they constantly bleed all day” and another reported their child’s “teeth and gums 
bleed for no apparent reason and this started when the child began taking non 
steroidal anti inflammatory drugs as part of their cancer therapy.”
3.1.5.4 Summary of gingival health.
The gingival health of the study population was similar to that of the general 
population. The number of boys affected by gingivitis was higher than the number of 
girls. There were no obvious differences in gingival health within tumour diagnostic or
treatment groups.
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3.1.6 Microdontia.
There were 26 microdont teeth present in 9 patients from the study population. All 
these patients had received chemotherapy under the age of 3.5 years.
Table 3.20 Relationship between microdont teeth and age at which chemotherapy 
was received.
number  (%) with 
Microdontia
number  (%) with No 
Microdontia
Chemotherapy given 
under 3.5 years old
 9 (11.4)  70 (88.6)
Chemotherapy given 
over 3.5 years of age
 0 (0.0) 41 (100.0)
Chi square analysis showed a significant p=0.025 (p<0.05) relationship between the 
age at which chemotherapy was received and the presence of microdont teeth. Using 
Fisher’s exact test to account for the small numbers the relationship was still found to 
be significant p=0.027 (p=<0.05) (appendix 16).
The group consisted of a mixture of tumour type rhabdomyosarcoma (2) 
neuroblastoma (3), hepatoblastoma, optic chiasm glioma, Wilm’s tumour and 
Hodgkin’s disease. 
97
Table 3.21 Details of microdont teeth within the study group.
Tooth Number of microdont teeth within the 
study group
Lower central incisor 2
Lower lateral incisor 2
Lower canine 2
Lower first pre-molar 5
Upper lateral incisor 3
Upper first pre-molar 5
Upper second pre-molar 4
Upper second molar 3
The type of treatment these children received was a mixture of chemotherapeutic 
agents as below in table 3.22. 
Table 3.22 Type of chemotherapy received by those with microdont teeth.
Chemotherapy regime Number of patients receiving that 
chemotherapy regime.
Anthracyclines 7
Alkylating agents 4
Platinum drugs 4
HDCSCR 3
One third of patients with microdont teeth had received HDCSCR.  Table 3.23 shows 
the relationship between the HDCSCR group with and without microdont permanent 
teeth.
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Table 3.23 Number of patients in the high dose chemotherapy and stem cell rescue
group with and without microdont teeth.
Microdontia no microdontia
HDCSCR 3 11
no HDCSCR 6 35
Chi square analysis of the data in table 3.23 demonstrated no significant relationship. 
Further research using larger numbers would be required to draw any conclusions 
(appendix 16).
Of the treatment groups the HDCSCR group did show the largest proportion of 
microdont teeth (see table 3.24). 
Table 3.24 Number of microdont teeth present in each group.
Group Number of Microdont 
teeth 
Number (%) patients with 
microdont teeth  in each group
HDCSCR n=14 3 3 (20.0)
Alkylating agents and no 
HDCSCR n=66
10 3 (4.6)
Anthracyclines and no 
HDCSCR n=66
12 3 (4.5)
Platinum drugs and no 
HDCSCR n=43
12 2 (6.7)
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Table 3.25 Number of microdont teeth within each diagnostic group.
Group Number of 
Microdont 
teeth 
Number of patients with microdont 
teeth (%) within each group
Hodgkin’s Lymphoma n=14 0 0 (0.0)
Neuroblastoma n=21 3 3 (14.2)
Non-Hodgkin’s Lymphoma 
n=10
4 1 (10.0)
Rhabdomyosarcoma n=10 6 2 (20.0)
Wilm’s tumour n=29 1 1 (3.4)
Other n=36 12 2 (5.5)
Table 3.25 shows the rhabdomyosarcoma group to have the highest percentage of 
patients affected with microdont teeth. However the neuroblastoma group 
demonstrated the largest number of patients affected with microdont teeth, but 
proportionally it is a smaller percentage due to the larger sample size.
3.1.7 Traumatised teeth.
Thirty two incisor teeth were traumatised in 21 patients within the study group.  
Fifteen patients had incisors in the adult dentition and six were in the deciduous 
dentition.  14 (66.7%) patients were male and 7 were female (33.3%)
Table 3.26 Traumatised teeth illustrated within diagnostic groups.
Group Number of  
traumatised teeth 
(TT)
Number of patients 
with TT (%)
Hodgkin’s Lymphoma n=14 1 1   (7.0)
Neuroblastoma n=21 5 4 (19.0)
Non-Hodgkin’s Lymphoma n=10 2 2   (20.0)
Rhabdomyosarcoma n=10 1 1 (10.0)
Wilm’s tumour n=29 11 7   (24.1)
Other n=36 13 6 (16.7)
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Table 3.27 Traumatised teeth present in each treatment group.
Group Traumatised 
teeth (TT)
Number (%) Patients 
with TT 
HDCSCR n=14 4 3 (20.0)
Alkylating agents and no HDCSCR n=66 16 11 (16.7)
Anthracyclines and no HDCSCR n=66 19 12 (18.2)
Platinum drugs and no HDCSCR n=43 8 4 (13. 3)
The results have not been compared directly with the 2003 CDHS age groups 
because in the study population there are no affected 8-year-olds and only one 
affected 12 and 15-year-old and therefore the numbers are too small to draw 
comparisons. Table 3.26 and 3.27 show that the highest number of traumatised teeth
were in the Wilm’s tumour, the alkylating agents and anthracycline drug treatment 
groups. However these were also the largest groups. The largest proportion of 
trauma was seen within the HDCSCR group. 
3.1.8 Fissure sealed teeth.
The study population included 32 sealed permanent teeth in 11 patients (9%, n=120).
When the study data by age group is compared to the 2003 CDHS data for England 
and the UK the study population is found to have a lower level of fissure sealants 
(table 3.28).
Table 3.28 Number of fissure sealants placed per age group.
Age 2003 CDHS 
England  fissured 
sealed permanent 
teeth %.
2003 UK
fissured sealed 
permanent teeth
%.
Study data
fissured sealed 
permanent teeth. 
Number (%)
8 11 13 0 (0.0%)
12 22 25  1 (14.3 %) 
15 28 30  3 (27.3 %)
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Figure 3.17
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Figure 3.17 shows no trend in patients with fissure sealants within the diagnostic 
study groups. The “other” group shows the smallest proportion of patients with fissure 
sealants. Again table 3.29 does not identify any trends in fissure sealant placement 
within the treatment groups. However the study group did have a below average 
incidence of fissure sealants.
Table 3.29 Number of fissure sealed teeth within each treatment group.
Group Fissure sealed 
teeth (FS)
Number  (%) patients 
with FS
HDCSCR  n=14 4  1 (6.6)
Alkylating agents and no 
HDCSCR  n=66
20  6 (9.0)
Anthracyclines and no HDCSCR 
n=66
19  7 (10.6)
Platinum drugs and no HDCSCR 
n=43
1 1 (3.3)
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3.1.9 Summary of key findings.
 The neuroblastoma and HDCSCR groups showed a higher level of primary 
dental decay compared with the general population and study population.
 All patients who had microdont teeth received chemotherapy under the age of 
three and a half years.
 The study group have a higher level of diffuse opacities by comparison with 
the general population.
 The prevalence of fissure sealants within the study population is decreased by 
comparison with the general population.
3.2 RESULTS AND ANALYSIS QUESTIONNAIRE (PART B).
This section reports responses to the questionnaire in part B of the study. 120 
questionnaires were part or fully completed by the parent/guardian of the patient.
3.2.1 Social class of the study group.
Questions 2-5 in the questionnaire were used to determine social class. Of 120 
questionnaires (one per family), 108 answered questions relating to the maternal 
parents/guardians and 96 regarding the paternal parents/guardians. The results of 
those parents (96 fathers and 108 mothers) who answered the relevant question 
according to the NS-SEC system are shown in figure 3.18. The relationship of the 
parents/guardians to the child, and with each other was not investigated within the 
current study. It is not known if the 12 mothers who did not state the “father’s” 
occupation and school leaving age were single parents or if those who stated both 
the mother’s and father’s occupations were married or not.
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Figure 3.18
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Using the Registrar General’s social class coding system the main categories are 
described below: 
I professional occupations.
II managerial and technical.
IIIN skilled-non-manual.
IIIM skilled manual.
IV partially skilled.
V unskilled.
(ONS, 1980)
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The results using the Registrar General’s coding system for those parents in the 
study population who answered the question alluding to social class are represented 
in figure 3.19.
Figure 3.19
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The results shown in figures 3.18 and 3.19 show a range of social backgrounds 
within the study group as would be expected in such a population.
Figure 3.20 illustrates the different ages of which the parents of the study group left 
full time education. This is a further way of mapping the socioeconomic status of 
individuals.
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Figure 3.20
Age at which parents within the study group finished full time 
education.
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This graph shows three peak times when full time education was finished. These 
were at 16, 18, and 21 years of age. These ages would account for those finishing 
after O-levels or GCSE’s, those after A-levels and those after a degree respectively. 
The older parents in the above graph have returned to education after a break.
3.2.2 Attitude.
Questions 1 and 7 of the questionnaire related to how important the parent 
answering the questionnaire felt looking after the mouth and teeth was. The first 
question concerned themselves and the second question concerned their child. A 
visual analogue scale was used for measurement of the perceived level of 
importance for both questions. 
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The first question (question 1) was answered by the parents in 62 cases (51.7%). 
When answering about the importance of oral health for their child (question 7) 117 
(97.5%) parents answered the question.  Figure 3.21 illustrates the results. The 
groups have been analysed in percentages to allow easier comparison.
Figure 3.21
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3.2.3 Reported attendance.
When asked about registration at a dental practice and how regularly the 
parent/guardian and child attended the results were the same for the child and 
parent/guardian (questions 6, 8 ,9).
Ninety nine (82.5%) parents reported their child to be registered with a general dental 
practitioner and 21 (17.5%) said they were not registered. The frequency of visits to a 
general dentist was described as below in figure 3.22.
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Figure 3.22
0
10
20
30
40
50
60
70
80
90
100
Number
Regularly Occasionally When trouble Never
Frequency
Frequency at which the parents and children of the study 
group attend the dentist.
Parent
Child
3.2.3.1 Prior to cancer therapy.
When asked if a dentist examined the teeth before cancer therapy started 14 (11.7%) 
said yes, 104 (86.7%) said no and 2 did not answer the question (question 10, 11). 
This question is subject to recall bias but despite this does show that most parents 
did not remember a dental review occurring as part of the preparation for 
commencing cancer therapy.
Of those who did recall a dental review before therapy, 1 stated that their child had
been seen locally and 5 stated their children had been seen within a hospital setting. 
It should be noted here that this result suggests 18 (15.0%) were seen by a dentist 
before cancer therapy started rather than the previously quoted 14 (11.7%). However 
the results still demonstrate that only a minority of patients are being seen by a 
dentist before cancer therapy commences.
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When enquiring what oral health advice has been received prior to starting cancer 
therapy; about how to look after the mouth and teeth during therapy, and the possible 
effects of cancer therapy on the mouth and teeth post therapy (questions 15,16) the 
response was as illustrated in figure 3.23.
 Figure 3.23
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3.2.3.2 During cancer therapy.
Question 17, 18 and 19 explore any oral health issues that arose during cancer 
therapy. The number of patients who reported side effects within the oral cavity 
during cancer therapy was 44 (37.6% n=117).
Figure 3.24
The proportion of the study cohort reported to have side effects within 
the oral cavity during cancer therapy.
3 (3%)
Unanswered
44 (37%)
Problems 
reported
73 (60%)
No problems
This pie chart shows that just over a third (37%) of patients can expect oral side 
effects when receiving treatment for a solid tumour. This emphasises the importance 
of preparing patients for the expected oral complications of cancer therapy.
The frequency of oral problems experienced by the patients are described in figure 
3.25. The ‘other’ category in figure 3.25 includes mucositis, sore teeth and pain on 
swallowing.
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The severity of complaints was established by asking all parents if the child required 
admission to hospital for medical treatment regarding the oral complaint during 
cancer therapy. This methodology may leave minor symptoms under-represented.
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Figure 3.26
Proportion of the study group admitted into hospital for supportive 
medical/dental treatment during cancer therapy.
4 (3%)
No answer
18 (15%)
Admitted
98 (82%)
Not admitted
Figure 3.26 indicates 15% of the study population were admitted to hospital during 
their cancer therapy requiring medical intervention for oral problems. This illustrates 
the importance of prevention of oral disease where possible.
3.2.3.3 After cancer therapy.
Parents were asked if they knew if the general dentist was still willing to see their 
child for reviews despite their medical diagnosis (question 14). Reassuringly 87 
(72.5%, n=120) said their dentist was willing to review their child and only 3 (2.5%, 
n=120) gave a definite no.
Ninety nine (82.5%, n=120) had been seen by the dentist since medical treatment
(question 12) had finished with the remainder not having been seen post cancer 
treatment. Of those seen the majority were seen within the general dental services
(question 20,22).
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The amount of dental treatment required since cancer therapy varied (question 21). 
Seventy six (63.8%, n=119) reported to have received some dental treatment and 43 
(36.1%, n=119) had not received anything other than a simple dental examination. Of 
those who needed treatment, the type, and frequency of treatment required is 
described in figure 3.27. 
Figure 3.27
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As with the dental reviews the required dental treatment is mainly carried out in the 
general dental service with only a small proportion requiring the hospital services. 
Figure 3.28 illustrates where dental care is sought within the study population.
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3.2.4 General dental care.
In general, parents were asked to comment on whether they felt their child had 
adequate dental care (question 23). The results are demonstrated in figure 3.29. 
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Figure 3.29
How parents felt about the level of dental care their child 
received.
87( 72%)
13 (11%)
14 (12%)
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Inadequate care
Don't know
Unanswered
The majority of parents felt they did receive adequate dental care. Remarks made in 
the ‘comments’ section occasionally supported this but there were other more 
worrying statements about the level of dental care accessed by the patients.
3.2.5 Questionnaire comments (question 24).
3.2.5.1 Comments supporting an adequate level of dental care.
‘No comments because our dentist is good’.
‘specialist dental care as child has autism.’
‘The previous dentist appeared not to be interested in her illness, just in general
dentistry but the practice has been taken over and we are due appointments within 
the next month.’
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3.2.5.2 Comments revealing inadequate dental care.
3.2.5.2.1 Difficult to access care.
‘2 abscesses during chemo -teeth extracted under local anaesthetic at BCH’
‘I am having serious problems getting my child into a dental surgery due to the fact I 
am unemployed. I am very worried about his teeth.’
‘it is very difficult to get appointments including check ups on time due to the size of 
the practice.’
‘Dentist said not to take her for 6 months. We need to re register as they have gone 
mainly private.’
‘waiting to see Birmingham Children’s Hospital dentist after being referred from the 
dental hospital’
The statements above support a common complaint that it is becoming increasingly 
difficult to seek care at a general national health service (NHS) dental practice.
3.2.5.2.2 Inadequate information received.
‘He was only 2 when diagnosed so we didn't worry about his teeth at the time. We 
hadn't started to visit the dentist but we were advised not to anyway.’
It is unlikely the oncology nurses would have advised a parent not to visit the dentist.
The parents were however obviously given this information somewhere.
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3.2.5.2.3 Lack of confidence in the general dentist.
‘not sure if local dentist is aware that chemotherapy could have caused dental 
problems’
‘dentist not sure how he would be with the anaesthetic.’
These statements suggest rightly or wrongly there is a lack of confidence by the 
parents in the general dental practitioners looking after these children. 
3.2.5.2.4 Orthodontic queries.
‘she has seen an orthodontist and she will need braces and removal of a few teeth. 
This obviously causes a problem unless the brace is not fixed due to the still having 
to have regular MRI scans (every 6 months)’
‘She has been told she needs a brace but there is a 2 year waiting list’.
‘concerns regarding milk teeth not dropping out with overcrowding and its making it 
hard to brush’
3.2.5.3 Miscellaneous comment.
‘I was told during treatment about problems with teeth that may occur but as my 
daughter had a lot of ulcers/soreness during treatment, cleaning was very difficult 
and we have had a lot of dental problems since.’
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4.0 DISCUSSION.
4. 1 REVIEW AND CRITIQUE OF METHODOLOGY.
Given the time and resource constraints available to the investigator the study was 
carried out as effectively and efficiently as possible and with strict adherence to the 
methodology as described previously. Despite this several improvements as 
described below could have been included in the methodology to improve the validity 
of the results.
1. Sample size. Although a large sample size was used there were so many 
variables that formal conclusions were difficult to draw. Ideally each diagnostic group 
would have been larger and the treatments standardised therefore limiting the 
variables as much as possible. Similar data could have been collected between 
centres improving the sample sizes and therefore the power of any calculations. This 
would lead to more solid conclusions and also allow comparisons between centres.
2. Control group. Age and sex matched control groups with the same demographics 
would have been preferable as a control group. Using this method both groups could 
be compared against each other and then also to the 2003 CDHS perhaps making 
the conclusions more valid for this cohort of patients.
3. Conditions of examination. Where possible the conditions matched those of the 
2003 CDHS. Ideally the enamel opacities would have been observed under natural 
light. The study took place in the only room available in the out patients department 
to the investigator at the time of the data collection. This room only had a small 
window high up. Therefore it was not practical to match this particular aspect.
4. Formal calibration of the primary investigator and another examiner.  Despite 
being trained, an official calibration was not recorded for the primary investigator. If 
this had been carried out it would have improved the validity of the results. During the 
data collection period unfortunately, due to staff shortages no other dental examiners 
could be present at the time of the dental examination of the patients and it was not 
practicable to bring the patients to a further appointment for a second examination by 
the primary investigator.
5. The Questionnaire. The questionnaire data could have been further validated by 
cross examining the patient notes to verify answers, in particular the questions about 
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problems experienced during chemotherapy which are subject to recall bias. The 
questionnaire itself could have been validated.
6. Data analysis.  Investigation of the enamel opacities should have looked into the 
postcode of the family from years 0-3. This would be when the tooth was at its most 
vulnerable developmentally.  Further analysis of the caries level in fluoridated and 
non fluoridated areas would be interesting to assess the effect fluoride had on caries 
within this population. Cross matching the questionnaire data and examination data 
would have allowed a more in depth analysis of the population however these further 
investigations were beyond the scope of this thesis.
4.2 REVIEW OF DEMOGRAPHICS AND COMPOSITION OF THE GROUP.
4.2.1 Number of patients.
The study population had 1) all experienced a solid tumour during childhood, 2) been 
treated with chemotherapy as part of their treatment regime and 3) attended the 
Birmingham Children’s Hospital (BCH) solid tumour follow up clinic. Children who had 
been treated with chemotherapy for brain tumours were included if they attended, but
most of this group are seen in a clinic on a different day. Given the rare nature of 
childhood cancer all patients who met the three inclusion criteria above were 
included. This allowed a sufficient sample size, but did result numerous variables 
within the study population. This should be taken into account when interpreting the 
results.  Considering the limited prevalence of solid tumours within the general 
population, despite the number of variables, this number of patients still represents 
one of the largest reported sample sizes. Other similar studies have been carried 
using smaller study groups (Holtta et al., 2005, Nunn et al., 1991, Maguire et al., 
1987).
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4.2.2 Geographical residence.
As Birmingham Children’s Hospital is a regional cancer centre the large spread of 
patients over the West Midlands and surrounding counties would be expected. CCLG 
registrations of cancer for children aged under 15 (2000-2005) have not shown any
particular area of the country to have higher solid tumour rates than others (CCLG, 
2007c). 
4.2.3 Social class.
The two different social class measurement scales are difficult to compare and draw 
any valid conclusions from as there are several differences between them. The NS-
SEC coding system is designed to be more flexible when placing occupations into 
categories.   Studies have shown there is an 87% level of continuity between the 
scales, (Rose and O'Reilly, 1998) therefore they cannot be directly compared with 
each other. Of the study population 18% preferred not to answer the questions 
alluding to social class but of those who did, using the national statistics 
socioeconomic classification, 44.8% of fathers and 30.5% of mothers were from 
managerial backgrounds, 9.4% of fathers and 15.7% of mothers from an intermediate 
background, 42.7% of fathers and 30.5% of mothers from routine and manual 
backgrounds and 3.1% of fathers and 23.1% of mothers were not employed. Both 
scales show a large spread of backgrounds within the study population as would be 
expected.  This is also supported by the data alluding to socio-economic status by 
recording at what age the parents/guardians left full time education. The study 
population shows a variety of ages with decreasing value peaks at 16, 18 and 21 
years (figure 3.20). The trend indicates fewer parents continued in full time education 
over time. These trends are supported by UK national statistics for the age at which 
students finish full time education. The number of children continuing in full time 
education is gradually increasing with 15% of 18-21-year-olds in full time education in 
1988-1989 and 30% of 18-21-year-olds in full time education in 1993-1994 (HEFCE, 
2001) but the pattern is still such that in the 2001 UK census 62% of 16-19-year-olds 
were still in full time education with 22% of 20-24-year-olds in full time education 
(ONS, 2004). This suggests there are more students finishing full time education at 
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16-18 by comparison with those completing higher education and finishing full time 
education at 21 years of age, within the general population.  Thus the graph 
described in figure 3.20 is suggestive of a mixed social population within the study 
group similar to that of the general population within the UK.  As the aetiology of 
childhood cancer is largely unknown it would be expected that the demographics of 
the study group reflect that of the average population.  
4.2.4 Medical diagnosis.
The main diagnostic groups included Wilm’s tumour, rhabdomyosarcoma, 
neuroblastoma and lymphomas. The relative proportions of medical diagnosis groups 
were as expected when based on the number and types of diagnoses of patients 
seen in the previous year and the prevalence of cancer types within the child 
population. These groups are also investigated by other authors. Näsman et al 
examined 24 children with a solid tumour of which 6 had Wilm’s tumour, 6 had 
rhabdomyosarcoma, 3 neuroblastoma, and 9 other solid tumours (Nasman et al., 
1997). Purdell–Lewis et al (1988) also observed 3 neuroblastoma , 6 Wilm’s tumour 
and 5 rhabdomyosarcoma patients (Purdell-Lewis et al., 1988). Many of the other
previous studies either clump together the solid tumour group (Karsila-Tenovuo et al., 
2001, Maguire et al., 1987) or are more focused on one particular group. For 
example Kaste et al (1998) studied 52 neuroblastoma patients (Kaste et al., 1998).
Höltta et al (2002) studied 18 neuroblastoma patients (Holtta et al., 2002). Alpaslan 
et al (1999) studied 30 children with non-Hodgkin’s and Hodgkin’s disease (Alpaslan 
et al., 1999). There was a spread of age at examination from 0-17 years with peaks 
at 5-7, 13 and 15 years. This reflects the nature of cancer as a disease process 
affecting a large variety of children at different ages. Some trends are apparent: for 
example the neuroblastoma and Wilm’s tumour group will include children diagnosed 
mainly under 5 years of age, as these tumours largely affect the younger age group.
However the study groups do include children of all ages because they have been 
under follow up for varying periods of time.
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4.2.5 Chemotherapy regime.
Analysis into the groups of high dose chemotherapy and stem cell rescue 
(HDCSCR), alkylating agents, anthracyclines and platinum drugs was performed as it 
was thought that these treatments would be more likely to affect the developing 
dentition. As seen in the Venn diagram, figure 3.5 there are some patients who have 
received more than one type of chemotherapy treatment regime. These individual 
groups were not analysed further due to the large number of different treatment 
regimes and the small patient numbers within the groups.
4.3 RATIONAL FOR CHOICE OF CONTROL DATA.
The Child Dental Health Survey 2003 (CDHS) was used to obtain control data. The 
CDHS was carried out in 2003 by dentists across the country on 5,8,12 and 15-year-
olds. An appropriate age and sex, matched control group was unobtainable in the 
scope of this study. This was because there were no identifiable healthy populations 
accessible through the Birmingham Children’s Hospital. The large variety of ages 
within the study group meant a control group would need to be made up from several 
sources and the time constraints of the research project precluded this. Previously 
school children have been used as a control group, it would however now be more 
difficult to obtain a sufficient sample size from this source as positive consent is likely 
to be required by the ethics boards to allow examination of the school children. The 
criteria used in this study were as close as possible to those used in the 2003 CDHS 
and the investigator carried out the same training in order to make the results as 
comparable as possible.
4.4 DENTAL CARIES.
Overall 42.2% of the study group had experienced decay in one or more teeth, 
18.3% had untreated primary decay and 18.3% had untreated secondary decay. The 
figures for the level of untreated decay are interesting because they are similar for 
both the primary and the permanent dentitions. The 2003 CDHS from 1983-2003
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reports that the number of restorations being placed in the primary dentition had 
declined in both 5 and 8-year-olds, but the proportion of filled permanent teeth had 
increased from 1983-2003 in 8, 12 and 15-year-olds. This data is calculated by 
measuring filled teeth as a percentage of obvious decay experience (Pitts and 
Harker, 2005). In the 2003 CDHS, 13% of 5-year-olds with obvious decay experience 
had filled teeth and 57% of 15-year-olds with obvious decay had filled teeth (Pitts and 
Harker, 2005). It is difficult to draw any comparisons with the above current study 
data because of the wide variety in age of the patients in the study group.
When comparing the study results with the 2003 CDHS directly by age groups, the 
only group which showed an increase in the level of decay was the primary dentition 
of 8-year-olds. The only group which showed a decreased level of decay was the 12-
year-olds in the permanent dentition. The other groups were all very similar. Given 
the small size of the study groups within the current study data it is difficult to draw 
any firm conclusions.
The groups showing a high dental caries rate in the primary dentition included the 
HDCSCR group and the neuroblastoma group. These results are largely based on 
the same patients because all patients who received HDCSCR had a neuroblastoma 
except for one patient. Kaste et al (1998) reported on 52 patients over a 31 year 
period of patients being treated for neuroblastoma and also noted an increased level 
of decay in the primary teeth. The caries experience of the permanent teeth was the 
same as the general population (Kaste et al., 1998); a finding consistent within the 
current study.  The increased decay rate could be attributed to the high level of 
systemic upset resulting from the cancer therapy. The chemotherapy the patients 
receive frequently results in the development of mucosal ulcerations and results in a 
sore mouth. During medical treatment the calorific intake for these children is 
important and it is often difficult to achieve an adequate level, hence these patients
will be fed on high calorific diets which, by their nature, are likely to be cariogenic. 
Also they are likely to be receiving more medical interventions with sweets often 
given as rewards thus contributing to a cariogenic diet. The chemotherapy during this 
period may cause a xerostomia, altered salivary consistency and disturbance in 
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taste, and therefore perhaps contribute to an increase in susceptibility to dental 
caries during this time. Often for cancers of younger children, the treatment affects 
an age group where the primary teeth are present and who require parental 
assistance to effectively brush their teeth. In this group dental hygiene may be sub-
optimal, especially in the presence of mucositis.
Apart from the above group, the caries experience of individuals in the study group 
does not seem to be above the level within the general population. This is shown by 
both the 2003 CDHS and The British Association for the Study of Community 
Dentistry (BASCD) epidemiological studies. The BASCD survey of 14-year-olds 
(2003) stated the mean DMFT over England and Wales to be 1.48 and the West 
Midlands is described as being below 1.24 (Pitts et al., 2004). The BASCD survey 
(2000) looking at 12-year-olds stated the DMFT to be 0.63 across the West Midlands
(Pitts et al., 2001). When comparing the study population (mean DMFT 0.56 and 
mean dmft 0.84) with the epidemiological studies described above, the study 
population does not have a particularly high caries rate. Apart from the 
neuroblastoma and HDCSCR group, the study population actually shows a decrease 
in caries experience compared with the general UK population. This finding is 
consistent with other groups of cancer patients and is supported by Alsplan et al 
(1999), Maguire et al (1987), Nunn et al (1991) and Oguz et al (2004), but 
unsupported by Purdell Lewis et al (1988) who found the caries experience of the 
cancer group to be higher than the controls. He did however use a different method 
of caries diagnosis. Caries in his study was defined by the presence of a white spot 
lesion, a criteria which would not be designated as caries by the 2003 CDHS (Pendry 
et al., 2004). The control group in the Purdell-Lewis et al (1988) study were recent 
longitudinal epidemiological studies that are reported to have used the same caries 
diagnosis criteria (Purdell-Lewis et al., 1988). Pajari et al (1988) also found a higher 
caries incidence in their cancer group by comparison with the healthy control group 
when using the World Health Organisation 1977 criteria for caries diagnosis (Pajari et 
al., 1988).
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4.5 ENAMEL OPACITIES.
Several different indices have been proposed to assess enamel opacities in teeth. 
The earliest index was by Murray and Shaw (Murray and Shaw, 1979). This included 
a 7 point index differentiating small white spots, larger white spots, coloured patches, 
horizontal lines, hypoplasia and possible early caries. A second index, called the 
defects of dental enamel index (DDE index) was introduced in 1981 by the general 
assembly of the world dental federation (FDI, 1982). This covered types of defect, the 
number of and demarcation of defects and the location of defects. This index was 
simplified and modified to include; normal, demarcated, diffuse and hypoplasia 
categories, also considering the extent of such lesions (Clarkson and O'Mullane, 
1989). The criteria used in the study population were as close as possible to the 
2003 CDHS to allow direct comparisons (Pendry et al., 2004). This index is based on 
the modified DDE index but included symmetry of diffuse lesions and codes 
accounting for the presence of, a mixture of lesions on a single tooth.
Of the study group tested 50 (62.5%, n=80) had enamel opacities present. The 2003
CDHS only recorded opacities in 12-year-olds. 35% of the 2003 CDHS 12-year-olds
in England were reported to have enamel opacities (Chadwick et al., 2006). Of the 
12-year-olds in the study population 3 (42.9% n=7) had enamel opacities. Due to the 
small sample size it is hard to draw any conclusions as none of the results were 
significantly different.
Within the study there were a large number of patients with diffuse defects, (42 
(52.5% n=80)) when compared with the 16% in the 2003 CDHS national data for 
diffuse opacities.  The 2003 CDHS report had as many demarcated (17%) lesions as 
diffuse (16%) lesions. This however was not a finding in the study population where 
the demarcated lesions were only noted in 12 (15% n=80) patients and diffuse 
lesions were noted in 42 (52.5%, n=80). The 2003 CDHS reported demarcated 
lesions to generally affect a smaller proportion of the tooth, with 92% being under 
1/3.  The current study supports this with 75% of demarcated lesions being under a 
third of the total tooth surface. Diffuse lesions are reported as being slightly more
125
widespread over the tooth surface, but still the majority in the 2003 CDHS (59%) are 
under a third of the tooth surface. The present study found 80% to be under a third
and fewer of the diffuse defects (13, 25.5% n=51) were symmetrical across the 
midline by comparison with the 2003 CDHS results which found 65% of diffuse 
defects to be symmetrical (Chadwick and Pendry, 2004).  Looking between the 
different sub-groups, there were no significant differences between them. The 
HDCSCR group did have the highest number (33.3% n=14) of patients with enamel 
opacities, but this was not significantly higher than the other groups.  The study 
showed a large number of diffuse opacities to have been present in those patients
living in a fluoridated area (38 patients in a fluoridated area compared with 12 
patients with opacities not living in a fluoridated area); a known cause of opacities 
that could be related to the effects of fluoridation as opposed to chemotherapy. 
However it is difficult to draw any firm conclusions from this data because analysis
was carried out using the present post code and assumes the patient has lived in a 
fluoridated all their lives which may not be the case. Further investigation of this was 
beyond the scope of the project.
Many of the other studies in the literature report cancer patients to have a higher 
incidence of enamel opacities and hypoplasias. Pajari et al (1988) studied 13 patients
who had received chemotherapy, who lived in a non or low fluoridated area and had 
similar diagnoses to the patients the study population. He reported a significant 
increase in opacities per patient compared with the control group using the 
Developmental Defects of Enamel Index (DDE index). Pajari’s study group had 100% 
with enamel opacities compared with the control group which had 86.5% with 
opacities. The results were not statistically significant. However, when they assessed 
the mean number of opacities per child, this was 10.4 in the cancer group and 3.4 in 
the control group showing a statistically significant difference in the level of opacities 
experienced (Pajari et al., 1988). Alpaslan et al (1999) who studied 30 lymphoma 
survivors also reported a significant difference between groups concerning opacities,
with more in the cancer group when tested by comparison with the control group. 
Fourteen patients (64 teeth) showed hypoplasias and 17 patients (147 teeth) showed 
discolourations compared with the control group of 20 healthy patients, where 3 
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patients (5 teeth) showed hypoplasia’s and one patient (4 teeth) showed 
discolourations. However, he did not explain the criteria used for this examination 
(Alpaslan et al., 1999). Maguire et al (1987) again found an increase in prevalence of 
enamel opacities (horizontal lines) and hypoplasia’s using the index described by 
Murray and Shaw (1979) but only in the upper teeth (Maguire et al., 1987). Purdell 
Lewis et al (1988) found 80% of the test group to have experienced enamel opacities 
using the DDE index and compared the data to the country’s national data which 
stated 43.3% as experiencing enamel opacities (Purdell-Lewis et al., 1988).  Nunn et 
al (1991), another study carried out in a known fluoridated area showed an increase 
in hypoplasias in the study group (7% in the siblings and 19% of the test group) but 
all other enamel defects, i.e. white patches, coloured patches and white lines (tested 
according to Murray and Shaws method (Murray and Shaw, 1979) were not found to 
be significantly different to the sibling group (Nunn et al., 1991). Given the number of 
different indices described it is difficult to draw conclusions about enamel opacities. 
However, many of the studies mention enamel opacities as a significant finding within
study populations. The cause of enamel opacities and hypolasias has been attributed 
to many different factors, one of which could be chemotherapy. Other factors include 
fluoride, spikes of temperature during fever and infections, nutritional deficiencies 
and trauma (Welbury, 2004).
4.6 GINGIVAL HEALTH.
The recording of gingival health in research studies is carried out using many 
different indices. The criteria indicative of “gingivitis” can be measured using non-
invasive, visual methods, invasive specific methods or both.  The gingival index first 
described by Loë (1967) is hierarchical and includes both a visual assessment, 
recording redness, oedema and glazing, and bleeding on probing (Loe, 1967). An 
example of a non-invasive method would be the modified gingival index. This scores 
gingival redness by observing the gingival margin and papillae visually only. It is 
modified from the original gingival index described above and therefore does not 
include bleeding on pressure (Lobene et al., 1986). More specific methods include 
the Community Periodontal Index of Treatment Needs (CPITN)  (Ainamo et al., 1982)
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and indices of bleeding on probing, which have been shown to indicate gingival 
inflammation (Greenstein, 1984). 
The current study recorded “gingivitis” by carrying out a basic periodontal 
examination on each patient (CPITN score) and then recording any sites of gingival 
bleeding on the mesial, distal, buccal and lingual aspect of each tooth. Any sites 
positive for bleeding indicated gingivitis. The 2003 Child Dental Health Survey
recorded gingivitis (as bleeding on probing) in 15-year-olds only (White and Lader, 
2004). The criteria used included 6 teeth; the first molars in each quadrant and the 
upper right central incisor and the lower left central incisor. The upper teeth were 
recorded by looking at the mesial, distal and buccal surfaces only and the lower teeth 
had the distal, mesial and lingual surfaces recorded only. If there was bleeding in any 
of the specified sites the subject was considered to have evidence of gingivitis
(Pendry et al., 2004). The specific data to match the above criteria was extracted 
from the present study data to allow comparisons. 
The gingival health of the study group when compared to the 2003 national data was 
slightly worse. Of the study population 54.5% showed signs of gingivitis (measured 
by bleeding on probing) compared to 43% of 15-year-olds in the UK. The current 
study also found more boys (62.5 %) to experience gingivitis compared with girls 
(33.3%). This finding is supported by Taani and Alhaija (2003) who investigated 
gingival health among 12-14-year-olds. They found that boys tend to have increased 
plaque levels and show poorer compliance with oral health measures (Taani and 
Alhaija, 2003). This is inconsistent with the 2003 CDHS results which reported more 
girls at 15 (46%) to be affected by gingivitis than boys (39%). However the 2003 
CDHS did report that this finding was inconsistent with earlier findings in the study,
when gingivitis was measured by looking at the mouth in sextants and marking where 
gingival inflammation was visually present.  The other studies in the literature report 
to have found no difference in gingivitis and the oral hygiene levels of test and control 
groups. This was also the finding of both Maguire et al (1987) and Alsplan et al
(1999); there were no studies supporting a difference. Despite these findings,
bleeding gums are a concern to parents during cancer therapy as described by the 
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parental statements in the comments section. Such findings can exacerbate parental 
anxiety over a child’s general health at a difficult time. Oral health education and 
improved preventative care may therefore reduce the level of anxiety felt by the 
parents and should be an important area for education, as part of the pre-treatment 
work up.
4.7 MICRODONTIA.
Microdontia was found in 9 of the study group patients. The most significant factor 
noted regarding microdont teeth, was that all patients who had a microdont tooth 
within the study population had received chemotherapy before the age of 3.5 years. 
When this relationship was investigated further it was found to be statistically 
significant, p=0.03. Maguire et al assessed the level of microdontia from radiographs 
by measuring crown size and found that within the solid tumour group 16.2% (n=37) 
had microdontia in the upper arch and 2.7% (n=37) in the lower arch. This however 
was not a test carried out in the sibling control group and therefore has no control 
comparisons. It is interesting to note that as with the study population, all children 
presenting with microdont teeth in the Maguire study received their chemotherapy 
treatment under the age of 3.5 years (Maguire et al., 1987).
The highest percentage of microdont teeth in the study data were found in the 
HDCSCR group (20%), whereas the other study groups with microdont teeth present 
were; alkylating agents (4.6%), anthracyclines (4.5%) and platinum drugs (6.7%).
This finding would be consistent with the type of medical treatment, as it is more 
likely to affect the developing germ cells in the developing dentition. However, the
results of the Chi squared test on the relationship between the HDCSCR treatment 
regime and microdont teeth was not statistically significant.
Because there is no current validated index classifying what a microdont tooth is, it is 
difficult to draw definitive conclusions and comparisons between studies. There are 
no epidemiological studies assessing microdontia in the UK population, but the paper 
by Holtta et al (2004) describes the Japanese population as having a prevalence of 
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1.9% microdontia when measured by taking casts of the teeth. Hawaiian studies 
show the prevalence to be higher at 3.1% (Holtta et al., 2004).
The most recent study investigating microdont teeth in this field is by Holtta et al 
(2004) (Holtta et al., 2004). They studied 55 patients who had received high dose 
chemotherapy under the age of 10 years and found microdontia in 44% of the study 
population against 2% in the control group. The control was the national 
epidemiological study data showing the Finish population to have a 2% incidence of 
microdontia. The investigators did acknowledge that the assessment of microdont 
was based on a subjective visual recording. If the investigators felt the size of the 
crown was at least 50% smaller than that of a ‘normally sized tooth’ it was labelled as 
microdont.  They found the most commonly affected teeth to be first premolars (46%) 
followed by second premolars (26%) and second molars (23%) (Holtta et al., 2004).  
These results are consistent with the findings of the current study population in that 
the first premolar (38.5%) was the most commonly affected tooth.
Microdontia is described as a common finding in other similar studies, but again the 
criteria for what a microdont tooth is, are not clear between studies. Holtta et al
(2002) looked at a group of 18 neuroblastoma survivors. These were split into two
groups, those who had received total body irradiation (tbi) and those who had not; all 
had received high dose chemotherapy. They found 80% and 87.5% of the tbi and 
non-tbi groups respectively to be affected by microdontia. The difference between the 
two groups was not significant but the group as a whole did show significant 
microdontia levels. Alpaslan et al (1999) reported to have found no microdontia in 
either the lymphoma or control group (Alpaslan et al., 1999).  Kaste et al (1998) 
studied microdontia from radiographs in their neuroblastoma study and reported 38% 
to have experienced microdontia. Again there was no control with this study and 
therefore the results are difficult to interpret (Kaste et al., 1998). Oguz et al (2004)
investigating the non-Hodgkin’s lymphoma group (n= 36) with an age and sex
matched control group (n= 36), assessed microdontia from radiographs and found 
3% of the test group to be affected by microdontia and 0% of the control group to be 
affected (Oguz et al., 2004). The literature therefore supports the finding of 
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microdontia in children who have received chemotherapy particularly those who had 
received chemotherapy at a young age, when the tooth germs are still developing.
From this data only limited observations can be drawn due to the small sample size. 
Microdontia and the presumed association with chemotherapy is well supported by 
several studies. However no studies actually define ‘microdontia.’ The teeth recorded 
in the current study as microdonts had an obviously smaller crown size than the 
expected size of the tooth in the investigator’s opinion. Many studies mention 
microdontia when analysing dental radiographs from patients who have received 
chemotherapy but none define the term. This is an area that requires a consensus 
opinion and diagnostic guidelines to establish consistency of reporting in future 
studies.
There are no epidemiological studies reporting the prevalence of microdontia in the 
UK population available in the literature. Comparisons can therefore only be made 
with other similar studies (Alpaslan et al., 1999, Holtta et al., 2004). As mentioned 
above this is difficult due to a lack of case definitions.
4.8 TRAUMA.
Dental trauma was experienced by 21 (17.5%, n=120) patients in the study group. As 
with national data the current study shows an increase in the prevalence of trauma in 
boys (66.7%) when compared with girls (33.3%). National data for 15-year-olds in 
England show 17% of boys and 10% of girls to have experienced dental trauma
(Chadwick and Pendry, 2004). This is most likely due to boys being more boisterous 
and participating in contact sports activities than girls.  There were no differences 
between the patient and treatment groups of the present study. These results 
suggest, despite possibly having more endotracheal intubations under general 
anaesthetic than the “average” child the patients within the current study group did 
not experience an increased level of dental trauma.
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4.9 FISSURE SEALANTS.
Fissure sealants have been shown to protect the occlusal surfaces of teeth against 
caries (McCune et al., 1979). A recent Cochrane review investigating the use of 
fissure sealants concluded fissure sealants are a recommended method of 
preventing occlusal caries in molar teeth. However the application of sealants should 
be based on the prevalence of caries in the individual and the local population 
(Ahovuo-Saloranta et al., 2004). A further Cochrane review investigating the use of 
fissure sealants versus fluoride applications concluded the application of fissure 
sealants to be superior to the application of fluoride varnish, but again the use of 
each should be based on the individuals concerned and local population needs (Hiiri 
et al., 2006).  The level of fissure sealants in the study population is low by
comparison with national data. Nine percent of the study population had fissure 
sealants compared with between 13-15% of 8, 12 and 15-year-olds in the 2003 
CDHS. This is possibly due to the fact that the caries rate is lower in the West 
Midlands and some dentists feel the need for fissure sealants in the Midlands area is
reduced by comparison with elsewhere in the UK. However, what was concerning
was that none of the patients in the neuroblastoma group and only 1 subject in the 
HDCSCR group received fissure sealants, when these are the two groups which 
would benefit the most from such a preventative technique.
4.10 QUESTIONNAIRE.
4.10.1 The use of questionnaires.
The questions were designed so as not to employ leading questions however the 
analysis of the results still has to take into account any bias. For example, the study 
group were asked to complete the questionnaire at the dental visit and so knew the 
investigator was a dentist which have could have led the person filling in the 
questionnaire to provide more favourable answers to ‘please’ the investigator. Also 
the questionnaire did require some recollection of information about when the child 
was initially diagnosed and initial treatment and therefore could be subject to recall 
bias.
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4.10.2 Attitude towards oral health.
The study group did appear to perceive oral health to be important according to the 
questionnaire answers.  Most parents/guardians answered favourably when 
considering the importance of oral health care in their child. 116 (99.1% n=117) 
crossed the line above 8cm and 70 (59.8% n=117) crossed at 10cm. One parent did 
cross the line at 5cm, but by the nature of the scale it is not certain quite how this 
parent actually felt about the oral health care of their child. It just gives an indication 
that they would not place oral health care at maximum importance.  Fewer 
parents/guardians answered questions about themselves. Of the 62 parents who 
answered about their perception of the importance of oral health care for themselves 
62 (100%) crossed the line above 6cm with 61.3% (38) crossing the line at 10 cm,
indicating maximum importance. The parents may have been reluctant to answer the 
question about themselves as they felt it was not important because the 
investigations were mainly about their child, or perhaps it was not noticed due to the 
position of the question on the paper. It should be remembered that, these answers 
will be subject to bias with parents perhaps answering more favourably than their day 
to day practice would support. 
4.10.3 Reported attendance at the dentist.
Of the parents who answered the question about how often they visit the dentist, 83 
(69.2%, n=118) reported to visit regularly, 21 (17.8%, n=118) reported to visit 
occasionally, 10 (8.5%, n=118) when in trouble and 4 (3.4%, n=118) never visited the 
dentist.
When answering about their child’s dental visits again 118 patients answered the 
question; 99 (82.5%, n=118) reported to be registered with a dentist; 91 (77.1%,
n=118) reported to visit regularly; 9 (7.6%, n=118) reported to visit occasionally with 
the same proportion visiting only when having trouble or never.  The CDHS has 
shown over the years that there is a positive correlation between the mother’s dental 
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attendance pattern and the child’s (Morris et al., 2004). Thus if the parents are 
regular attenders the child is likely to be so. This theory was supported by the current
data.
The study data when compared with the national data from the same question asked 
in the 2003 CDHS does show similar responses (question 6). 2003 CDHS results 
show 82-88% 5-15-year-olds reported to visit regularly, 8-14% occasionally and 3-5% 
when in trouble. From the 2003 CDHS data those who had never visited the dentist 
were 7% of 5-year-olds and 1% of 15-year-olds (Morris et al., 2004). This does 
indicate that the study group had a high level of patients who had never attended the 
dentist. There was one 5-year-old, two 9-year-olds and 4 teenagers who had never 
been to the dentist. Given the nature of the disease the patients had experienced and 
the tumour’s medical treatment, these figures, though within a small sample size, are 
disappointing. The findings of the study do emphasise the importance of receiving 
some dental input within this particular group of patients.
It is interesting to note that in April 2005, before this study’s data collection phase 
began, the National Health Service (NHS) general dental services within England 
changed their structure. Instead of being paid on a fee per item basis the services 
have moved towards “salaries” for general dentists. The system for patients also 
changed and now patients are no longer officially registered with a specific dental 
practice, but anyone who attends requesting a dental review and course of dental 
treatment should be accepted, provided that dentist has not exceeded his NHS 
contract value for that year. This change is poorly understood by the general 
population at the present time. However future research may be unable to ask the 
question about registration at the general dental practice, because it will no longer be 
a valid measure. It would be interesting to research the impact of the new system 
within such population groups. Already, as shown in the comments section, several 
remarks were made expressing concerns over access to a national health service 
dentist, mentioning their dentist had “gone private” or the practice was so busy that it 
was difficult to obtain review appointments.
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4.10.3.1 Prior to cancer therapy.
Before starting cancer therapy only 14 (11.8% n=118) reported to have specifically 
seen the dentist, the remainder answered “no” (104, 88.2% n=118). When asked 
where they were seen, 18 parents answered the question of which 13 were seen 
locally and 5 by a hospital dentist. These figures are below the ideal. The 
UKCCSG/PONF mouth care guidelines (UKCCSG and PONF, 2006) now suggest 
every patient should be specifically screened by a dentist before starting cancer 
therapy in an attempt to prevent any unnecessary dental complications during cancer 
treatment. Often during this time the child is immunosuppressed and any treatment of 
dental disease becomes more complicated. The seriousness of complications is 
highlighted by the study data stating 40% of those patients who did experience 
problems with the oral cavity did required hospital admission. It may be useful from a 
protocol, to include a hospital dental review on the same day that all the other pre-
treatment medical tests are carried out. This would identify problems and allow 
arrangements to be made to address any pre-existing dental disease before 
chemotherapy was due to start.
Information on how to look after the mouth and teeth during cancer therapy was
reported to have been given in 52 cases (44.1% n=118), 12 (10.2% n=118) did not 
know and 53 (44.9%, n=118) specifically claimed they did not receive any 
information.  The possible long term sequelae are reported to have been discussed 
in 69 (59.0% n=117) cases, with 34 (28.8%, n=117) specifically saying no discussion 
occurred and 14 (12.0%, n=117) having not remembered if this was discussed or not. 
One parent did mention in the comments section they felt “more information at the 
time of treatment verbally’” would help. These questions are both subject to recall 
bias. More recently the level of general information given to patients on the diagnosis 
of cancer has improved. However, upon the diagnosis of cancer so much information 
will be given to the families regarding the medical treatment required and its late 
effects on the whole body, it is possible the oral effects are forgotten (or over looked)
as other effects seem more significant. It may be helpful to develop a leaflet to give to 
parents for future reference once the cancer therapy has started. Despite having no 
teeth this information should also be given to the parents of very young children. The 
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comment ‘he was only 2 when diagnosed so we didn't worry about his teeth at the 
time. We hadn't started to visit the dentist but we were advised not to anyway’ 
highlights how at least one family felt this issue was unimportant at such a young age 
yet this is the age where the developing dentition is most vulnerable and the families 
should be warned of potential issues during treatment and the potential late effects.
4.10.3.2 During cancer therapy.
Forty four (37.6% n=117) parents did report problems with their child’s mouth during 
cancer therapy. The most frequently reported problem was a sore mouth (36, 55.4% 
n=65) followed by 12 (18.5%, n=65) complaining of a mouth infection, 8 (12.3%, 
n=65) dental decay and 9 (13.8%, n=65) other complaints including ulcers, mucositis, 
sore teeth or difficulty swallowing. Of these 18 (40% n=65) required hospital 
admission. Those requiring hospital admission often require supportive therapy for 
oral pain control and provision of fluids due to a sore mouth and inability to swallow. 
Mucositis is difficult to predict and cannot be easily prevented. It has been shown to 
occur in 30-75% of patients undergoing chemotherapy (Fulton et al., 2002, Dodd et 
al., 2000). More accurate incidences of mucositis, xerostomia and taste disturbance 
during chemotherapy for solid tumours are difficult to find in the literature and would 
be worth exploring further, however this was beyond the scope of this thesis. It is 
difficult to fully assess the impact of pre-existing dental disease during the time
chemotherapy is undertaken. In the comments section of the questionnaire, one 
parent did write it was necessary for their child to have two teeth removed due to 
dental abscesses whilst mid-chemotherapy. This acute scenario could probably have 
been avoided if a dental review had been carried out before the chemotherapy 
commenced.
4.10.3.3 After cancer therapy.
Since medical treatment finished 99 patients (83.2%, n=119) reported to have seen a 
dentist and the majority (79, 67.0%, n=118) had seen a local dentist. When 
considering the results of this question it should be remembered the question was 
potentially subject to recall bias and also may have been more favourably answered 
to ‘please’ the investigator as it was being completed at the time of the dental 
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examination. According to the results most patients are still being seen within the 
general dental services. This is supported by the fact that 87 (73.7%, n=118) general 
dentists would happily see their child despite the medical treatment and condition 
and only 3 (2.5%, n= 118) specifically saying “no” to treating the patient. Provided the 
patients are accessing oral health care and their general dentist is managing any 
problems adequately, no specialist input would be required. If necessary the general 
dentist can refer the child to the hospital service for an opinion or treatment if 
required. What was more worrying was that 21 (17.5%, n=120) patients had not 
sought any dental care after the treatment for their cancer. This number may be 
slightly inflated due to the fact that 8 patients had finished their therapy within the 
previous 6 months. Taking this into account along with the potentially more 
favourable results there were still at least 13 patients who should have received a 
dental review and had not.
4.10.4 Dental treatment required post cancer therapy.
Since cancer therapy finished, 63.9% (76 out of 119) reported to have had dental 
treatment carried out. This data is subject to recall bias and may not be factually 
accurate. Parents could have mis-interpreted the dentists explanation of treatment 
carried out or simply have forgotten exactly what happened. Of this group 26 (39.3%, 
n=66) had required fillings, 9 (13.6%) extractions under local anaesthetic, 4 (6%) 
extractions under general anaesthetic and 4 (6%) were undergoing orthodontic 
treatment. This treatment was provided by the local dentist in 39 (33.3% n=117) 
cases and in hospital for 7 cases (6.0%). These findings show that the majority of 
care is still being received within the general dental services despite the medical 
history, therefore suggesting that some patients who are able to seek care within the 
general dental services do receive adequate care. With changes to NHS dentistry 
this may change.
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4.10.5 General dental care and comments made.
In general 87 (76.3%, n=114) felt they did have adequate access to dental care, 13 
(11.4%, n=114) felt they did not have adequate care and 14 (12.3%,n=114 ) did not 
know if they had adequate dental care.  These findings suggest 27 (23.7%, n=114) of 
the study population were not receiving, in their parents opinion, adequate dental 
care. It would be interesting if interviews of these patients and their parents were 
carried out, to ascertain why they felt this way and whether or not there was a real 
need for arrangements to be made for these children to be reviewed within the 
hospital system.  Despite the figure of 76.3% who felt they did have adequate access 
to dental care there were several comments to the contrary. The comment ‘2 
abscesses during chemo- teeth extracted under local anaesthetic at BCH’ highlights 
the need for a dental review before commencing chemotherapy and potential 
inadequate dental care being received. If a screening examination had taken place it 
would have been likely that these teeth would have been identified and extracted or 
restored before chemotherapy started, therefore not causing further complications 
during the period of chemotherapy.  Active disease was noted in during the 
examination in 30.8% of the study population, and upon questioning some of the 
families had no readily available dental care and were therefore referred or seen at 
BCH. In further studies it would be interesting to cross match the dental examination 
with the questionnaire answers to investigate how many of these patients had 
recorded in question 23, to have felt they did have adequate dental care. 
When considering the overall results, it is important to note the answers given on all 
the questionnaires are likely to be slightly in favour of good oral health practices. This 
was because the parents/guardians knew the investigator was a dentist and were 
therefore more likely to write favourable answers, some of the questions were also 
subject to recall bias as it may have been some time since the event occurred.
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5.0 CONCLUSIONS, OUTCOMES AND FUTURE RESEARCH.
5.1 CONCLUSIONS.
1. The study group of solid tumour patients did not have significantly more dental 
complications in comparison with the general population. 
2. The study group did require a greater dental input in comparison with the general 
population particularly during chemotherapy treatment.
3. The oral health needs of individual groups of solid tumour oncology patients did 
differ according to the type of tumour and treatment regime. The oral health needs of 
the neuroblastoma patient group and those patients receiving high dose 
chemotherapy with stem cell rescue (HDCSCR) were increased when compared to 
the remaining study and general population. These groups require a greater dental 
input with more emphasis on prevention techniques such as fissure sealants, oral 
health care regimes and long term dental follow up to address the likely dental 
anomalies occurring.
4. In general the study patients did not have difficulty in accessing dental care at the 
present time. Though in some cases this was not perceived to be satisfactory care.
5. There was a varied level of knowledge of oral health care implications in parents
following their childs cancer therapy.
6. Children receiving chemotherapy under the ages of 3.5 years appear more likely to 
have one or more microdont teeth in the adult dentition by comparison with those 
who are older when they receive their chemotherapy.
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CLINICAL RECOMMENDATIONS.
Clear protocols and care pathways should be created for the solid tumour patients 
regarding oral health care upon diagnosis, during chemotherapy and after 
chemotherapy.
It is recommended that a dental examination is carried out for all patients before 
commencing chemotherapy and regular follow up is continued throughout the 
therapy and the teenage years. If the child does have a family dentist, the dental 
reviews can be carried out within the general dental services, but should the level of 
care not suffice, the hospital dental specialities team should provide oral health care 
for this group of patients. Information sheets should be designed for general dental 
practitioner’s to explain the short term and long term oral health problems these 
patients may be facing and what oral health interventions are recommended before, 
during and after cancer therapy.
With the recent re-structuring of NHS dentistry and the unknown outcome of such 
changes it may be advisable to provide hospital surveillance for those patients being 
reviewed within the general dental services. If patients are found to have difficulties in 
accessing care, oral health log books could be designed such that for children who 
change general dental practitioners frequently all of the relevant medical and dental 
information would be readily accessible to each different practitioner. These books 
would be held by the parents/guardians of the child (similar to the way the ‘red book’ 
for young children is used for general health records) and therefore ease the 
transition among different dental practitioner’s, record what interventions had been 
required in the past and facilitate hospital surveillance ensuring adequate oral health 
care for patients. 
Urgent care should be available to these patients through the hospital, particularly if 
dental treatment is required to achieve a healthy mouth before the patient starts 
chemotherapy.
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Training should be available for the oncology team regarding the effects of cancer 
therapy on the dentition, signs and symptoms of oral disease and where and how to 
seek further advice when it is required. Regular updates and training of new 
members of the oncology team should be regularly provided by the dental team 
within the community and hospital environments. 
Verbal and written information should be provided about the effects of chemotherapy 
on the oral cavity and the teeth. This should cover the oral health side effects during 
chemotherapy and also cover long term effects such as microdontia and other dental 
anomalies. Different information leaflets should be designed explaining the above 
information aimed at children of different ages and their parents/guardians. The 
information should be available in different languages and approval for the use of the 
symbol of clarity (a crystal) sought from the Plain English Campaign.
Greater dental input is required for the neuroblastoma and HDCSCR group with 
development of separate protocols for these patients. Of all the oncology patients this 
group are most likely to benefit from a dental screening appointment by a dental 
specialist pre-treatment as the consequences of sepsis are significantly detrimental 
to their health. They are the group which need most help with prevention and 
reinforcement of prevention with support for the parents on oral health care. They are 
also likely to need the most dental intervention in the future due to the increased 
possibility of dental anomalies. It should perhaps be suggested this group are seen 
by a specialist paediatric dentist and fissure sealants are provided as a preventative 
measure in all cases.
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5.3 FUTURE RESEARCH.
To enable the collection of reliable epidemiological data that records the level of 
microdont teeth within the general population and specific study population groups 
further research into microdont teeth is required. A consensus of opinion on the 
definition of a “microdont tooth” should be sought with a proposed scale of 
measurement. The development of such an index would allow comparable data 
between studies researching similar subjects to be calculated. This is important for 
subject areas such as the current study, where obtaining large numbers of subjects is 
difficult due to the rare nature of the disease.
Further long term follow up studies of neuroblastoma and HDCSCR patients would 
be beneficial to investigate the oral health effects of chemotherapy treatment further.
These patients have been shown in the current study to be the most “at risk” patients 
for long term oral health side effects of their treatment. There are few studies 
investigating the long term health outcomes for these patients because previously 
many patients died as a result of their disease however with newer treatment 
regimes the survival rate has significantly improved.
Research into the frequency of oral health problems during the chemotherapy phase 
of solid tumour cancer treatment would also help our understanding of the short term 
oral side effects of chemotherapy. Investigating the exact number of patients 
requiring supportive therapy from the hospital during therapy and the incidence of 
mucositis, xerostomia, taste disturbance would help in the preparation of the patients 
for chemotherapy. Further trials of how best to treat these side effects are also 
required as also mentioned by the recent Cochrane review on oral mucositis
(Worthington et al., 2005). 
During the planning and data collection phases of this research study the general 
dental services in England were restructured. Instead of a general dentist looking 
after a cohort of the general public and being paid on a “fee per item” basis, they 
have moved to obtaining a contract with the local health authority. This enables the 
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dentist to undertake so many units of dental activity a year for which they are paid a 
salary. The provision of out of hours care is no longer the responsibility of the dentist 
and the patient is no longer “registered” with that dentist. If therefore the dentist has 
fulfilled the contracted units of required dental activity before the end of the contract 
period they can no longer see further patients under the National Health Service 
regulations until a new contract begins. The effects concerning the provision of oral 
health care following the change in structure of the general dental services to the 
general population and in particular this group of patients should be reviewed and 
investigated again.
The dental examination and questionnaire results could be crossed matched to allow 
a more in depth analysis of the current or future populations. The data collection 
might be expanded to include patients such as those with central nervous system 
tumours and those with leukaemia. This would enable a larger study population and 
possibly highlight further differences in oral health between different types of cancer.
Multi centre trials would also be beneficial to increase the overall numbers of patients 
and the diagnostic group numbers.
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APPENDIX 1.
Data collection sheet 1.
Identification code:
Hospital number:
Date today:
Date of birth:
Gender:
Postcode:
Diagnosis:
Date of diagnosis:
Treatment regime:
Chemotherapy Chemotherapy and Radiotherapy
Radiotherapy Observation
Length of chemotherapy treatment:
Date started the follow up clinic:
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APPENDIX 2.
Data Collection sheet 2
Identification code:
Dental Examination:
 Teeth Present
 DMFT
1,7 6 5 4 3 2 1 E D C B A A B C D E 1 2 3 4 5 6 2,7
D
O
M
B
L
D
O
M
B
L
4,7 6 5 4 3 2 1 E D C B A A B C D E 1 2 3 4 5 6 3,7
Codes:
0= sound
1= arrested caries
2= decayed
3= unrestorable
4= filled and decayed
5= filled with no decay
R= filed but needs replacing
6= extracted due to caries
7= extracted due to orthodontic reasons
8= unerupted
9= excluded 
$- sealant
N= sealant restoration
T= traumatised
C= crown/ advanced restoration
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Data collection sheet 2
Identification code……
BPE score:
Tooth 1,6 1,1 2,1 2,6
Code
Tooth 4,6 4,1 3,1 3,6
Code
Scores:  0=healthy
   1= bleeding on probing
   2= calculus
   3= shallow pockets 4-5mm
   4= deep pockets 6mm+
   *= furcation or recession of 7mm+
7-11   years only use codes 0,1,2
12-16 full coding but above teeth used only
>16    full BPE
If above 16 years
Use table below for adult BPE scoring.
Periodontal Health
1,7 6 5 4 3 2 1 E D C B A A B C D E 1 2 3 4 5 6 2,7
D
O
M
B
L
D
O
M
B
L
4,7 6 5 4 3 2 1 E D C B A A B C D E 1 2 3 4 5 6 3,7
Code 0= no bleeding from the gingival sulcus.
Code 1= bleeding from the gingival sulcus.
Code 9= assessment cannot be made.
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APPENDIX 3.
Identification code……
Opacities
Consent for photo: yes/no
(please circle)
Tooth 1,4 1,3 1,2 1,1 2,1 2,2 2,3 2,4
Type of defect
Extent of 
defect
Symmetry
TYPE OF DEFECT:
Code 0- normal
Code 1- demarcated opacity
Code 2- diffuse opacity
Code 3- hypoplasia
Code 4- demarcated + diffuse
Code 5- demarcated +hypoplasia
Code 6- diffuse+ hypoplasia
Code 7- all 3 defects
Code 8- other defects
Code 9- Assessment cannot be made
EXTENT OF DEFECT:
Code 0- normal 
Code 1- less than 1/3
Code 2- at least 1/3-2/3
Code 3- at least 2/3
Code 9- assessment cannot be made
If more that 2/3 is decayed fractured it should not be examined
Symmetry of defect:
Code-0= no diffuse defects
Code 1= diffuse defects but not symmetrical
Code 2= diffuse defects symmetrical
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APPENDIX 4
Version 3.0. 03/12/05
Dear Parent/Guardian,
I am writing to you to inform you about some research that is currently being carried 
out at Birmingham Children’s Hospital on patients who attend the late effects clinic 
and wish to participate. 
We are looking into the short term and the long term effects of cancer treatment on 
children and young adults’ teeth and mouth.
Your child is being invited to take part at their next follow up clinic appointment. This 
is on a purely voluntary basis and will not affect the medical care he/she receives it 
will however increase the amount of time you spent at the hospital.
Please read the enclosed information leaflet regarding the study and consider 
whether you wish your child to take part. By taking part your child will help improve 
our knowledge about the dental health of children with cancer and enable us to 
improve services appropriately.  Any questions or queries can be answered at your 
appointment.
Thanking you in anticipation
Yours Sincerely
Alison Hutton
Specialist Registrar in Paediatric Dentistry
[address]
[phone number] 
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APPENDIX 5 
Version 5.0   03/12/05
Patient Information Sheet  for Parents/Guardians Group 1.
Study Title:
The Dental Needs of Children Undergoing Cancer Treatment for Solid Tumours.
Invitation to Participate
You and your child are being invited to take part in a research study. Before you 
decide it is important for you to understand why the research is being done and what 
it will involve.  Please take time to read the following information carefully and 
discuss it with others if you wish.  Ask us if there is anything that is not clear or if you 
would like more information.  Take time to decide whether or not you wish to take 
part.
It is known that children who have, or have been treated for leukaemia have more 
dental problems than children who have not. There is less evidence available for 
children who have been treated for solid tumours. This project aims to examine a 
cross section of children who are under follow-up for the treatment of solid tumours at 
Birmingham Children’s Hospital to identify what dental problems they have and 
assess whether they have access to adequate dental care.
1.  What is the purpose of the study?
Research in children with leukaemia has identified that sometimes children have 
increased need for dental care during and after treatment. Less research has been 
carried out in children with solid tumours. Potentially there may be an increased risk 
of problems for the teeth and mouth even after treatment has finished. Some studies 
of adult survivors of childhood cancer have commented that individuals find it difficult 
to access dental care.
Preventing dental disease will help to improve overall health. The effects of treatment 
for their malignancy on the development of the teeth and function of oral tissue will 
be assessed in children taking part in the study. 
This survey aims to look at the dental health of a cross section of children treated for 
solid tumours of childhood who are attending the follow-up clinic at Birmingham 
Children’s Hospital. It will also record the extent of input that children are receiving 
from their own dentist or community dental services.
2.  Why has my child been chosen to take part in the study?
Your child has received treatment for a solid tumour of childhood and is attending the 
follow up clinic in the oncology department at Birmingham Children’s Hospital.
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3.  Do they have to take part?
No. It is up to you and your child to decide whether or not to take part. If you decide 
to take part you are still free to withdraw at any time and without giving a reason.  A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive.
4.  What will happen to my child if he/she takes part?
If your child chooses to take part they will see a dentist for a dental examination 
taking approximately 10mins. If he/she is over 7 years old a photograph will be taken 
of the front teeth and they will be asked to have an x-ray of the teeth in the dental 
hospital. You will be asked to fill out a short questionnaire about your child’s current 
dental treatment.
5.  What do I have to do?
When you attend the clinic for a regular follow-up appointment your child once you 
have read this information sheet again you will be asked to sign a consent form if you 
agree for your child to take part. Your child will then also be seen by the dentist and 
you will be asked to fill out a short questionnaire. If your child is over 7 years old a 
photograph will be taken of your child’s teeth and you will be asked if you would be 
willing to attend the dental hospital (which is next door to the Children’s Hospital) for 
an X-ray of the teeth.
6.  What are the alternatives?
If you do not wish to take part in the study your child can continue to receive their 
usual care from their own dentist or community dental services.
7.  What are the side-effects of any treatment received when taking part?
This study is an examination only. There is no treatment involved. If the dentist 
considers that your child does require treatment they will inform your child’s dentist or 
community dental service, or if necessary refer your child to the dental clinic at 
Birmingham Children’s Hospital.
8.  What are the disadvantages and risks of taking part?
The only disadvantage is extending your clinic visit for the time required for the 
examination, to complete the questionnaire and to have the X-ray of the teeth. Your 
child will be exposed to some radiation when we take the x-ray. This is a very small 
dose of radiation equivalent to 2 days of background radiation from being outdoors.
9.  What are the possible benefits of taking part?
If early dental disease is discovered it will be possible to treat this before symptoms 
such as toothache develop.
10.  What if new information becomes available?
It is unlikely that new information relevant to this study will become available while it 
is in progress.
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11.  What happens when the research study stops?
Your dentist or community dental services will be informed of the results of the 
examination and the X-ray. If you do not have a dentist advice about how to obtain 
dental services will be given.
12.  What if something goes wrong?
There is no treatment involved in this study.
13.  Will my child taking part in this study be kept confidential?
Yes. All information about your child will be kept anonymous. The results will be 
published in a scientific paper, but there is no way that any individual could be 
identified from the information that is given. The photograph of your child’s teeth will 
be kept confidentially and used for research. In the event that we wished to publish 
the photograph of your child’s teeth or the X-ray of your child’s teeth for illustration in 
any scientific paper we would approach you for consent to do that at the time.
14.  What will happen to the results of the research study?
The results will be analysed and published in a scientific paper.
15.  Who is organising and funding the research?
The research is organised and funded between the oncology and dental departments 
of Birmingham Children’s Hospital and the Paedodontics department at the 
Birmingham Dental Hospital.
16.  Whom do I contact for further information?
If you have any questions please contact [details]
17.  What if I have any concerns?
If you have any concerns or questions about the study you could contact [details]
Thank you for taking time to read this information.
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APPENDIX 6 
Version 5.0   14/12/05
Patient Information Sheet  for adolescents 16+ 
Study Title:
The Dental Needs of Children Undergoing Cancer Treatment for Solid Tumours.
Invitation to Participate
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it
with others if you wish.  Ask us if there is anything that is not clear or if you would like 
more information.  Take time to decide whether or not you wish to take part.
It is known that children who have, or have been treated for leukaemia have more 
dental problems than children who have not. There is less evidence available for 
children who have been treated for solid tumours. This project aims to examine a 
cross section of children who are under follow-up for the treatment of solid tumours at 
Birmingham Children’s Hospital to identify what dental problems they have and 
assess whether they have access to adequate dental care.
1.  What is the purpose of the study?
Research in children with leukaemia has identified that sometimes children have 
increased need for dental care during and after treatment. Less research has been 
carried out in children with solid tumours. Potentially there may be an increased risk 
of problems for the teeth and mouth even after treatment has finished. Some studies 
of adult survivors of childhood cancer have commented that individuals find it difficult 
to access dental care.
Preventing dental disease will help to improve overall health. The effects of treatment 
for their malignancy on the development of the teeth and function of oral tissue will 
be assessed in children taking part in the study. 
This survey aims to look at the dental health of a cross section of children treated for 
solid tumours of childhood who are attending the follow-up clinic at Birmingham 
Children’s Hospital. It will also record the extent of input that children are receiving 
from their own dentist or community dental services.
2.  Why have I been chosen to take part in the study?
You have received treatment for a solid tumour of childhood and are attending the 
follow up clinic in the oncology department at Birmingham Children’s Hospital.
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3.  Do I have to take part?
No. It is up to you to decide whether or not to take part. If you decide to take part you 
are still free to withdraw at any time and without giving a reason.  A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of 
care you receive.
4.  What will happen to me if I take part?
If you choose to take part you will see a dentist for a dental examination taking 
approximately 10mins. A photograph will be taken of the front teeth and you will be 
asked to have an x-ray of the teeth in the dental hospital. Your parent/guardian will 
be asked to fill out a short questionnaire about your current dental treatment.
5.  What do I have to do?
When you attend the clinic for a regular follow-up appointment once you have read 
this information sheet again you will be asked to sign a consent form if you agree for 
your child to take part. You will then also be seen by the dentist and your 
parent/guardian will be asked to fill out a short questionnaire. A photograph will be 
taken of your front teeth and you will be asked if you would be willing to attend the 
dental hospital (which is next door to the Children’s Hospital) for an X-ray of the 
teeth.
6.  What are the alternatives?
If you do not wish to take part in the study you can continue to receive your usual 
care from your own dentist or community dental services.
7.  What are the side-effects of any treatment received when taking part?
This study is an examination only. There is no treatment involved. If the dentist 
considers that you require dental treatment they will inform your dentist or community 
dental service, or if necessary refer you to the dental clinic at Birmingham Children’s 
Hospital.
8.  What are the disadvantages and risks of taking part?
The only disadvantage is extending your clinic visit for the time required for the 
examination, to complete the questionnaire and to have the X-ray of the teeth. You 
will be exposed to some radiation when we take the x-ray. This is a very small dose 
of radiation equivalent to about 2 days of background.
9.  What are the possible benefits of taking part?
If early dental disease is discovered it will be possible to treat this before symptoms 
such as toothache develop.
10.  What if new information becomes available?
It is unlikely that new information relevant to this study will become available while it 
is in progress.
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11.  What happens when the research study stops?
Your dentist or community dental services will be informed of the results of the 
examination and the X-ray. If you do not have a dentist advice about how to obtain 
dental services will be given.
12.  What if something goes wrong?
There is no treatment involved in this study.
13.  Will my taking part in this study be kept confidential?
Yes. All information about you will be kept anonymous. The results will be published 
in a scientific paper, but there is no way that any individual could be identified from 
the information that is given. The photograph of you teeth will be kept confidentially 
and used for research. In the event that we wished to publish the photograph of your 
teeth or the X-ray of your teeth for illustration in any scientific paper we would 
approach you for consent to do that at the time.
14.  What will happen to the results of the research study?
The results will be analysed and published in a scientific paper.
15.  Who is organising and funding the research?
The research is organised and funded between the oncology and dental departments 
of Birmingham Children’s Hospital and the Paedodontics department at the 
Birmingham Dental Hospital.
16.  Whom do I contact for further information?
If you have any questions please contact [details]
17.  What if I have any concerns?
If you have any concerns or questions about the study you could contact [details]
Thank you for taking time to read this information.
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APPENDIX 7
Version 4.0
03/12/05
Patient Information Sheet 13-15 yrs Group 1.
Study Title:
The Dental Needs of Children Undergoing Cancer Treatment for Solid Tumours.
You are being invited to take part in a research study. It is important for you to 
understand why the research is being done and what it will involve.  Please take time 
to read the following information carefully and discuss it with others if you wish.  Ask 
us if there is anything that is not clear or if you would like more information.  Take 
time to decide whether or not you wish take part.
It is known that children who have, or have been treated for leukaemia have more 
dental problems than children who have not. There is less evidence available for 
children who have been treated for solid tumours. This project aims to examine 
children who are under follow-up for the treatment of solid tumours at Birmingham 
Children’s Hospital to identify what dental problems they have and assess whether 
they have access to adequate dental care.
1.  What is the purpose of the study?
Research in children with leukaemia has identified that sometimes children have 
increased need for dental care during and after treatment. Less research has been 
carried out in children with solid tumours. Potentially there may be an increased risk 
of problems for the teeth and mouth even after treatment has finished. Some studies 
of adult survivors of childhood cancer have commented that individuals find it difficult 
to access dental care.
Preventing dental disease will help to improve overall health. The effects of treatment 
for the tumour on the development of the dentition and function of oral tissue will be 
assessed. 
This survey aims to look at the dental health of a cross section of children treated for 
solid tumours of childhood who are attending the follow-up clinic at Birmingham 
Children’s Hospital. It will also record the extent of input that children are receiving 
from their own dentist or community dental services.
2.  Why have I been chosen?
You have received treatment for a solid tumour of childhood and are attending the 
follow-up clinic in the oncology department at Birmingham Children’s Hospital.
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3.  Do I have to take part?
No.  It is up to you to decide whether or not you take part. If you decide to take part 
you are still free to withdraw at any time and without giving a reason.  A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of 
care you receive.
4.  What will happen to me if I take part?
You will see a dentist in the oncology clinic for a dental examination taking 
approximately 10 minutes, a photograph will be taken of your front teeth only and you 
will be asked to have an x-ray of the teeth in the dental hospital. Your 
parent/guardian will be asked to fill out a questionnaire about your current dental 
treatment.
5.  What do I have to do?
When you attend the clinic for your regular follow-up appointment if you agree and 
your parent/guardian has signed a consent form you will also be seen by the dentist 
and your parent/guardian will be asked to fill out a short questionnaire. A photograph 
will be taken of your front teeth and you will be asked if you would be willing to attend 
the dental hospital (which is next door to the Children’s Hospital) for an X-ray of the 
teeth.
6.  What are the alternatives?
If you do not wish to take part in the study you can continue to receive your usual 
care from your own dentist or community dental services.
7.  What are the side-effects of any treatment received when taking part?
This study is an examination only. There is no treatment involved. If the dentist 
considers that you do require treatment they will inform your dentist or community 
dental service, or if necessary refer you to the dental clinic at Birmingham Children’s 
Hospital.
8.  What are the disadvantages and risks of taking part?
The only disadvantage is extending your clinic visit for the time required for the 
examination, for your parent to complete the questionnaire and to have the X-ray of 
the teeth. You will be exposed to some radiation when we take the x-ray. This is a 
very small dose of radiation equivalent to 2 days of background radiation from 
outdoors.
9.  What are the possible benefits of taking part?
If early dental disease is discovered it will be possible to treat this before symptoms 
such as toothache develop.
10.  What if new information becomes available?
It is unlikely that new information relevant to this study will become available while it 
is in progress.
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11.  What happens when the research study stops?
Your dentist or community dental services will be informed of the results of the 
examination and the X-ray. If you do not have a dentist advice about how to obtain 
dental services will be given.
12.  What if something goes wrong?
There is no treatment involved in this study.
13.  Will my taking part in this study be kept confidential?
Yes. All information about you will be kept anonymous. The results will be published 
in a scientific paper, but there is no way that any individual could be identified from 
the information that is given. The photograph of your teeth will be kept confidentially 
and used for research. In the event that we wished to publish the photograph of you 
teeth or the X-ray of you teeth for illustration in any scientific paper we would 
approach you for consent to do that at the time.
14.  What will happen to the results of the research study?
The results will be analysed and published in a scientific paper.
15.  Who is organising and funding the research?
The research is organised and funded between the oncology and dental departments 
of Birmingham Children’s Hospital and the Periodontics department at the 
Birmingham Dental Hospital.
16.  Whom do I contact for further information?
If you have any questions please contact [details]
17.  What if I have any concerns?
If you have any concerns or questions about the study you could contact [details]
Thank you for taking time to read this information.
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APPENDIX 8
Version 4.0
03/12/05
Patient Information Sheet 8-12 yrs Group 1.
You are being invited to take part in a research study. Think about whether or not you 
wish take part. Ask us or your parent or guardian if there is anything you do not 
understand.  
1.  Why are we doing a study?   
Dentists have found patients who have had cancer as a child sometimes do not have 
dental treatment before, during and after their illness. The treatment you have 
received for the cancer can sometimes make your mouth sore during treatment and 
can occasionally affect the developing teeth. 
We want to find out if this is true. Then we can make dental services better where 
they are needed.
2.  Why have I been chosen to take part in the study?
You have been chosen to take part because you have had treatment for cancer 
during childhood.
3.  Do I have to take part?
No it is your choice.
4.  What will happen to me if I take part?
If you choose to take part you will see a dentist for a dental check up taking 
approximately 10mins, a photograph will then be taken of your front teeth in the 
medical illustration department and then you will then be required to go to the dental 
hospital for an x-ray of the teeth. Your parent/guardian will be asked to fill out a 
questionnaire regarding your dental experiences
5.  What are the possible disadvantages and risks of taking part?
You will have to give up some of your time to allow the dental examinations to take 
place. You will be exposed to a very small amount of radiation when we take the x-
ray. 
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6.  What are the possible benefits of taking part?
You will help us find out if chemotherapy treatment does have an effect on your 
teeth. This may help us with treatment of our patients in the future by identifying any 
problems you have experienced.
You will be told if any dental treatment is needed and advised on where to seek 
treatment if you do not already have a dentist.
7.  Will my taking part in this study be kept confidential?
Yes.
8.  Whom do I contact for further information?
If you have any questions please contact [details]
9.  What if I have any concerns?
If you have any concerns or questions about the study you could contact [details]
Thank you for taking time to read this information.
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APPENDIX 9
Version 2.0
03/12/05
Patient Information Sheet under 8 yrs Group 1.
You are being invited to take part in a special study. 
This means some dentists and doctors are seeing if the treatment you have had for 
your illness has had any affect on your teeth so far.
They are doing this because they are not really sure if it does or not. If it does the 
information they get will help other boys and girls with the same illness as you.
If you do want to help you will have to sit in the chair and let the dentist look at your 
teeth.
If you don’t want to take part its ok no-one will mind.
Contact for Further Information
If you have any questions please contact [details]
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APPENDIX 10
Patient identification number:                  Version 2.0      03/12/05
Research project consent form
Title:
The dental needs of children, adolescents and young adults undergoing cancer 
treatment for solid tumours.
Researcher: Alison Hutton
I confirm the nature and purpose of this study has been explained 
to me by reading the patient information leaflet.  Any further 
questions have been answered.
I agree for my child to participate in the study and understand that I or my child may 
withdraw at any time without giving reason and without any detrimental effect to 
medical or dental treatment and care.
Signed……………………………………………Date………………………..
Chief Investigator
Signed…………………………………………….Date………………………….
Child’s signature (if child wishes to sign)
Signed…………………………………………… Date…………………………
Name………………………Relationship to the child……………..……………
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APPENDIX 11.
Identification code…………………..              Version 5.0.  21/12/05
1.  How important do you think it is to look after your mouth and teeth?
     Please indicate with an x where you feel is most appropriate on the line.
NOT AT ALL IMPORTANT VERY IMPORTANT
The following questions are placed so we can put all the data into certain 
categories for data analysis. This project’s data will be compared to national 
data gained in the Child Dental Health Survey which has the same categories. If 
you do not wish to answer the questions please move to question 6.
2.  Could you tell us about the current job of the child’s father or male head of the 
household or the last job he did if he is currently not doing any paid work? If he is no 
longer living in the house with the child please go to question 4.
Occupation of father/male guardian………………………… 
3. What age did/will the father or male guardian finish full time education?
4.  Could you tell us about the current job of the child’s mother or female guardian or 
the last job she did if she is currently not doing any paid work? If she is no longer 
living in the house with the child please go to question 6.
Occupation of mother/female guardian……………………………..
5.  What age did the mother or female guardian finish full time education?
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Identification code………………….. Version 5.0  21/12/05
6.  Do you generally visit the dentist. regularly (every 6 months)
Please tick appropriate answer occasionally (less frequent checkups)
only when having trouble with the teeth
Never
THE FOLLOWING QUESTIONS REFER TO THE CHILD WHO IS ATTENDING 
THE FOLLOW UP CLINIC.
7.  How important do you think it is to look after your child’s mouth and teeth?
     Please indicate with an x where you feel is most appropriate on the line.
NOT AT ALL IMPORTANT VERY IMPORTANT
9. Does your child generally visit the regularly (every 6 months)
    dentist… occasionally (less frequent checkups)
Please tick appropriate answer only when having trouble with the teeth
Never
11. If so who examined your childs’ teeth? local dentist
Please tick appropriate answer hospital dentist
community dentist.
8. Does your child have a local family dentist?                                        yes no
10. Did anyone arrange for your child to be examined by a dentist yes no
before starting medical treatment for cancer?
If no please move to question 12
12.Has your child been seen by a dentist since medical treatment yes no
finished? If no please move to question 14.
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Identification code………………….. Version 5.0 21/12/05
13. If so who examined your childs’ teeth? Local dentist
Please tick appropriate answer hospital dentist
community dentist.
 14. Is your child’s own dentist still willing to see your child despite the yes no
 past medical treatment?                don’t know
           not applicable
15. Did you have any information on how to look after your child’s yes no
mouth and teeth during cancer treatment?       don’t know
16. Have any possible effects of the medical treatment on your     yes no
child’s mouth and teeth been discussed with you?         don’t know
17. Did your child have to go into hospital and stay for treatment yes no
       because of a sore mouth during his/her chemotherapy?
18. Did your child have any problems with his/her mouth or teeth yes no
    during chemotherapy?
If no please move to question 20.
19. If so what kind of problems occurred? sore mouth
Please tick any appropriate answers decayed teeth
mouth infection
other (please specify)……………………………………..
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Identification code…………………..                Version 5.0 21/12/05
23. Do you think your child has adequate dental care? yes no
             don’t know
24. Is there anything you would like to say about the dental treatment of your child?
Please write any comments below.
Thank you for your time.
20. Has your child had any dental treatment carried out since yes no
chemotherapy finished?
If no please move to question 23.
21. If so what kind of treatment was this? teeth filled
Please tick any appropriate answers teeth taken out under local anaesthetic
teeth taken out under general anaesthetic
Painting/sealing of teeth
Cleaning of teeth
orthodontic treatment (braces)
               other (please specify)….……………………………
22. If so who provided the treatment for your child? local dentist
Please tick appropriate answer hospital dentist
community dentist.
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APPENDIX  12
 
[Not available in this web version] 
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APPENDIX 13
[Not available in this web version]  
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APPENDIX 14
[Not available in this web version]  
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APPENDIX 15
[Not available in this web version]  
183
APPENDIX 16
CHI SQUARE TEST RESULTS
1. The relationship between the presence of opacities and the level of fluoride in the water supply.
Actual
Fluoride(F) No Fluoride Row 
Total
Opacities 3 11 14
No opacities 6 35 41
Col.Total 9 46 55
Expected
Opacities 2.29 11.71 Chi square 
probability
No opacities 6.71 34.29 0.553 (N/S)
2. The relationship between the type of opaque defect and the level of fluoride in the water supply.
Actual Fluoride(F) No Fluoride Row 
Total
Demarcated opacities 8 4 12
Diffuse opacities 33 9 42
Col.Total 41 13 54
Expected
Demarcated opacities 9.11 2.89 Chi square 
probability
Diffuse opacities 31.89 10.11 0.395 N/S)
3. The relationship between the age at which chemotherapy was received and the presence of
    microdont teeth.
Actual microdontia no microdontia Row total
Chemotherapy 
age<3.5years
9 70 79
Chemotherapy 
age>3.5years
0 41 41
Col.Total 9 111 120
Expected
Chemotherapy 
age<3.5years
6.13 72.87 Chi square 
probability
Chemotherapy 
age>3.5years
2.87 34.13 0.025 Significant
4. The relationship between the use of high dose chemotherapy and stem cell rescue as a treatment
    and microdont teeth.
Actual microdontia no microdontia Row total
HDCSCR 3 11 14
No HDCSCR 6 35 41
Col.Total 9 46 55
Expected
HDCSCR 2.29 11.71 Chi square 
probability
No HDCSCR 6.71 34.29 0.553 (N/S)
